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ABSTRACT OF DISSERTATION 
 
 
 
 
DEVELOPMENT OF A MOLDABLE COMPOSITE BONE GRAFT SUBSTITUTE 
RELEASING ANTIBACTERIAL AND OSTEOGENIC DRUGS 
 
Large infected bone defects (IBD) are very complicated to treat due to their high 
variability; they often require multiple procedures.  Bone autografts are the gold standard 
for treatment but have several drawbacks, such as a need for a second surgery site, 
limited grafting material, and donor site morbidity.  The objective of this research was to 
develop a moldable synthetic bone grafting material capable of releasing both 
antimicrobial and osteogenic drugs over a clinically relevant time course for the treatment 
of IBDs.  Current treatment methods for large IBDs require two separate procedures to 
treat the bone defect and the infection.   
This research sought to combine these two procedures into one implantable 
composite bone graft substitute for the treatment IBDs.  To begin, the degradation and 
mechanical properties of the calcium sulfate (CS) based composite material were 
evaluated for different compositions.  Next, the controlled drug release profiles from the 
composite was achieved by using a shell and core system incorporating poly(lactic-co-
glycolic acid) microspheres (PLGAms).  The release of vancomycin from the shell began 
immediately and continued over the course of 6 weeks, while the release of simvastatin 
from the core was delayed before being released over 4 weeks.  Next, an infected, 
critically-sized rat femoral defect model was used to test different treatment methods with 
and without the composite bone graft substitute.  Animals treated with locally released 
antibiotics had survivorship rates 24% higher than those treated with systemic antibiotics, 
and animals that received both antibiotics and an osteogenic drug had an increased 
amount of bone formation at 12 weeks compared to controls.   
Finally, several different anti-biofilm agents were evaluated for their ability to 
inhibit and/or disrupt the growth of Staphylococcus aureus (S. aureus) biofilms in vitro.  
Lysostaphin was the only drug investigated that was able to both inhibit and disrupt S. 
aureus biofilms.  Furthermore, lysostaphin encapsulated into PLGAms maintained its 
bioactivity and may be useful for future incorporation into biofilm-combating materials.  
The bone grafting material developed here can be used to locally deliver drugs in a 
temporally controlled manner to reduce the number of procedures necessary for the 
treatment of complex IBDs.  
 
KEYWORDS: Biofilms, bone graft substitute, calcium sulfate, composite, 
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Chapter 1 Introduction 
Unlike simple fractures, the human body cannot heal large bone defects 
spontaneously and requires surgical intervention in the form of bone fixation and grafting 
[1, 2].  This is necessary due to the tendency of fast growing scar tissue to grow within 
the defect, preventing the slower growing bone from being able to bridge the gap [3].  
Bone grafts are used to maintain the space within the defect and stimulate bone healing 
without hindering growth [4, 5].  The primary material used in bone grafting is 
autologous bone, or bone harvested from the patient’s own body [6].  Autologous bone 
grafting is the gold standard method of treatment due to its inclusion of osteogenic cells, 
low risk of infection, and no risk of rejection [3, 6].  Even with all the success of bone 
autografts there are still significant drawbacks, such as limited grafting material and the 
need for a second surgery site [3, 7].  Anytime a large bone graft is needed there has 
likely been significant damage to the surrounding soft tissue and, with this, a high chance 
of infection [8, 9].  This infection complicates the bone healing process and needs to be 
eliminated before grafting and fixation can be performed [2, 10, 11].  The primary aim of 
this research was to develop a moldable bone grafting substitute capable of delivering 
antibiotics and osteogenic drugs in a temporally controlled manner for the treatment of 
large infected bone defects (IBDs) without the need for autologous bone.   
Chapter two examines the background and significance of current treatment 
methods for infected bone defects as well as discussing bone autografts, allografts, and 
many of the common synthetic substitute materials.  A brief introduction to bacterial 
biofilms and how they relate to large bone defects is also discussed.  In chapter three the 
ratio of calcium sulfate (CS), bio-polymer, polymer microsphere, or antibiotic was 
investigated for the effects on overall mechanical properties of the bone graft substitute.  
The effects of various setting environments such as air, incubator, or saline solution were 
also examined.  Chapter four discusses the method and rationale for designing a temporal 
separation in the release of the antibiotic and osteogenic drugs.  In vitro release profiles 
and bioactivity of released antibiotic against Staphylococcus aureus (S. aureus) are also 
presented.  In chapter five the in vivo effectiveness of the two part composite bone graft 
substitute is evaluated in a critically sized rat femoral defect model. The ability of the 
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bone graft substitute to eliminate an acute or chronic infection and stimulate the bone 
healing process was evaluated at four and twelve weeks through observation, 
histological, and radiographic techniques.  Chapter six explores alternative treatment 
options for bacterial biofilms which could be incorporated into future therapeutic 
biomaterials.  Lysostaphin is an antibacterial enzyme which is capable of both inhibiting 
biofilm formation and disrupting established biofilms.  This enzyme is loaded into 
poly(lactic-co-glycolic acid) (PLGA) microspheres for in vitro release studies and 
bioactivity against S. aureus.  Finally, chapter seven will discuss the effectiveness of the 
moldable bone graft substitute at treating large infected bone defects and potential ideas 
for the material to better treat biofilm infections.  
3 
 
Chapter 2 Background and Significance 
 
2.1 Infected Bone Defects 
The typical causes of large IBDs are high energy traumas such as explosions, car 
accidents, or gunshot wounds [3, 12, 13].  Because of this a large number of IBDs are 
seen in military conflicts [14-16].  Approximately 80% of injuries sustained during 
Operations Enduring Freedom and Iraqi Freedom are the result of explosions and 50-85% 
of these become infected [14-17].  The majority of these injuries are sustained in the 
extremities where less protective equipment is worn [17].  In a prospective study on the 
treatment of lower extremity open fractures, the outcomes of treatment with either soap 
or antibiotic solution during irrigation were compared to the outcomes in terms of 
infection and the healing of the soft and hard tissue [9].  This study found that 
approximately 37-41% of patients that presented with an open lower extremity fracture 
showed signs of gross contamination and after treatment there was still a 13-18% chance 
of developing an infection [9].  A study by Harris et al. following lower extremity trauma 
found that the most common complication was infection in 34% of patients [8].  One of 
the most common types of organisms that occurs in trauma related infection is the Gram 
positive bacteria S. aureus [18, 19].  This is due to the prevalence of the S. aureus on 
human skin and its propensity to adhere to cartilage and bone [19-21].  Other bacterial 
species that are commonly found include Streptococcus pyogenes, Streptococcus 
pneumonia, Escherichia coli, and Pseudomonas aeruginosa [20]. 
 
2.2 Current Treatment Methods  
 Because of the large variability in size and location associated with IBDs, 
successful treatment can necessitate multiple procedures and be very challenging [13, 22-
24].  In order to properly heal the bone defect, the infection must be taken care of first [2, 
10, 11].  This is due to a number of different ways that the infection can negatively affect 
the outcome of the bone grafting procedure [18, 20, 21].  In order to implant a bone graft 
into a segmental defect, the free ends of bone must first be fixed, usually with implanted 
hardware such as plates, rods, and pins [2, 10, 11].  If the fixation hardware was 
implanted before the infection had been eliminated the bacteria could colonize the foreign 
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object within the wound site [1, 25, 26].  Once the bacteria had colonized the implant a 
bacterial biofilm could form, which is a sessile community of bacterial cells which 
secrete extracellular polymeric substances (EPS) that greatly reduce the effectiveness of 
most antimicrobials [27-29].  A chronic infection like a biofilm will also cause persistent 
local inflammation, a decrease in pH, and a decrease in oxygen levels [18, 20, 21].  These 
effects along with the damage that the bone has already suffered as a result of trauma can 
cause additional bone to be lost as the infection grows [30, 31].  In order to avoid this, 
treatment for IBDs begins with a series of extensive surgical debridements and irrigations 
to remove any infected or necrotic tissue [2, 10, 11].  The patient is also put on a regime 
of systemic and local antibiotics to help combat the infection [2, 10, 11].  Once the 
infection has been eliminated the process of fixing the bone and grafting can begin.  The 
gold standard of grating materials has been autologous bone for a very long time due to 
its success at stimulating new bone growth and no risk of rejection [6, 24]. 
 
2.3 History of Bone Grafting 
The first ever recorded bone graft occurred in 1668 by Job van Meek'ren, a Dutch 
surgeon [32-34].  In this procedure a piece of a dog skull was used as a xenograft to 
repair a soldier’s skull [32-34].    A xenograft is a graft where the tissue comes from a 
different species, and unfortunately the soldier had to have the graft removed two years 
later after being excommunicated from the church [32-34].  Autografts, which involve 
harvesting the donor bone from the patient, have been used for over 100 years [6, 24].  
Major reasons for their success are the incorporation of osteogenic cells, the use of an 
osteoconductive matrix, and no risk of rejection [3, 35].  Despite all their success, 
autografts still have several disadvantages such as the need for a second surgery site, 
limited grafting material, and donor site morbidity [35].   Allografts are a common 
alternative to autografts because they do not involve harvesting bone from the patient but 
from cadavers [6, 7].  This allows for more grafting material to be obtained and removes 
the need to perform an additional surgery on the patient; however there is an increased 
risk of diseases transmission and they do not contain the osteogenic cells that make 
autografts so effective [6].  In the 1960's a US surgeon named Marshall Urist discovered 
bone morphogenetic proteins (BMPs), growth factors belonging to the transforming 
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growth factor-beta (TGF-β) superfamily [36, 37].  Of particular interest to bone healing 
are BMP-2 and BMP-7 which are powerful osteoinductive growth factors [36, 38, 39]. 
 
2.4 Bone Graft Substitutes 
Due to the limitations and drawbacks of bone autografts and allografts there has 
been much research into the development of bone graft substitutes [3, 6, 40].  Bone graft 
substitutes aim to replace the current gold standard treatment of bone autografts by 
stimulating bone healing and often by delivering antimicrobials, something that can’t be 
done with traditional autografts [3, 6].  Ceramics such as calcium sulfate (CS), calcium 
phosphate (CaP), or hydroxyapatite (HA) are common materials used in these substitute 
materials due to their high biocompatibility and moderate strength [5, 41-43].   
Calcium sulfate has been used as a bone grafting material for over 100 years and is 
biodegradable, biocompatible, and osteoconductive [22, 44, 45].  Calcium sulfate is often 
formed into pellets which are loaded with antimicrobials and packed into wounds to 
provide local delivery at the site of infection [40, 46].  Antimicrobials delivered in this 
manner release the majority of the loaded drug within the first 2-3 days and frequently 
drop below the minimum inhibitory concentration (MIC), which can lead to resistant 
strains of bacteria if the pellets do not degrade quickly enough or are removed [47, 48].  
In a prospective study performed by Kelly et al., patients with bone defects were treated 
with calcium sulfate pellets instead of the more traditional cancellous bone graft [44]. 
The CS pellets were either used alone or mixed with autografts, demineralized bone 
matrix, or bone marrow aspirate [44].  Patients were followed for 12 months and the 
defects were monitored at 1, 2, 3, 6, and 12 months radiographically [44].  The amount of 
grafting material left in the defect and the percentage of new bone ingrowth was 
quantified [44].  All groups of CS pellets showed 99% resorption and 88% of the bone 
void filling after six months, and only 3.6% developed complications related to the 
implanted material [44].  This study shows the viability of CS as a bone grafting 
substitute by itself but also as an expander material to increase the volume of autogenous 
bone grafts [44].  In another prospective study performed by McKee et al. antibiotic-
loaded calcium sulfate beads were used to treat chronic long bone infections or an 
infected non-union and compared to similar cases which were treated with antibiotic 
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loaded poly(methyl methacrylate) (PMMA) beads [40].  The primary outcome of the 
study was to remove the infection and the secondary outcomes were to have new bone 
growth, achieve union, and reduce the number of complications/repeat operations [40].  
In the calcium sulfate group, the infection was removed in 86% of the patients and seven 
of eight were able to achieve union [40].  In the PMMA group the infection was removed 
in 86% of the patients and six of eight were able to achieve union [40].  While there was 
no significant difference between the antimicrobial and bone forming properties of the 
two groups, there was a significant difference in the number of additional procedures 
required after treatment, with the PMMA group requiring a total of 15 further surgeries 
compared to seven in the calcium sulfate group [40].  This difference was accounted for 
by the additional procedures required to retrieve some of the PMMA beads that were 
interfering with the healing process since they are not biodegradable [40].    This 
preliminary study was able to show that calcium sulfate beads were comparable in most 
aspects of treating infected non-unions and even reduced the additional procedures 
required when compared to the more standard method of using PMMA beads [40]. 
 Calcium phosphate is another bone graft substitute material that has been used 
since 1892 and is biodegradable, biocompatible, and osteoconductive [49, 50].  Calcium 
phosphates are typically stronger than CS based materials and degrade much more slowly 
[49, 50].  Similar to CS pellets, CaP can be used as a bone cement loaded with 
antimicrobials or growth factors and formed into pellets for packing into wounds [49, 
50].  When used in pellet form a large burst release of drug is typically seen, followed by 
sub MIC levels for an extended period of time that can require surgical removal of the 
pellets even though the materials are biodegradable [51, 52].  Calcium phosphate bone 
cements, which are often used to fix or coat metal hardware, cannot be removed after the 
burst release of drug, increasing the chance of delivering sub-MIC levels of 
antimicrobials [51].  In a study by Field et al., a femoral defect was created in sheep and 
treated with either autografts or tricalcium phosphate (TCP) granules [49].  The sheep 
were evaluated radiographically at two, four, and six months and using computed 
tomography after euthanasia [49].  The animals with autografts showed good bone 
ingrowth after two to four months while the TCP granules did not show much until six 
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months [49].  The lag in bone growth could be accounted for by the lack of any 
osteoinductive agents in the TCP group when compared to the osteoinductive autografts. 
In addition to the ceramic based bone graft substitutes there is also significant 
interest in the development of polymer based materials such as PMMA, polyurethane, 
poly(lactic acid) (PLA), and PLGA [53-55].  Unlike many of the ceramic based bone 
graft substitutes, polymer based materials are not usually inherently osteoconductive and 
thus require the addition of an antibiotic or osteogenic factor to be effective in the 
treatment of bone defects [56].  For example, Zong et al. compared a PLA/PLGA and 
PLA/nano-hydroxyapatite (nHA) scaffold seeded with human bone marrow-derived 
mesenchymal stem cells ability to regrow bone within a rat calvarial defect [53].  It was 
found that both scaffolds showed bone formation within the defect area but that the 
PLA/PLGA scaffold had more mature bone formation and degraded faster than the 
PLA/nHA, making room for new bone formation [53].  Yoshii et al. showed that a 
polyurethane scaffold containing lovastatin, a known osteogenic drug, showed increased 
bone formation at four weeks compared to a polyurethane control in a rat plug defect 
model [54]. 
Moldable bone graft substitutes have several advantages over preset pellets, 
including being easier to handle and being better able to fill irregularly shaped bone 
defects [5, 57, 58].  By filling more of the space within the defect, moldable bone graft 
substitutes can better limit soft tissue ingrowth and minimize the space between the 
native tissue and implanted material [3].  A common method of creating a moldable bone 
graft substitute is the addition of a biocompatible polymer.  Examples of such polymers 
include: carboxymethyl cellulose (CMC), sodium alginate, PLGA microspheres, 
poly(ethylene glycol) (PEG), and hyaluronan (HY) [5, 42, 57, 59, 60].  In a study by 
Reynolds et al. CS was mixed with CMC and demineralized bone matrix (DBM) and 
compared to CS and DBM alone in a critical sized rat calvarial defect [5].  The CMC 
group showed comparable amounts of bone formation, fibrous tissue, and residual 
material after 28 days but was found to have superior handling properties [5].   Urban et 
al. found similar results when investigating a CS and hydroxypropylmethylcellulose bone 
grafting putty which had similar resorption and bone formation as a CS paste alone in a 
critically sized canine humeri model [61].  These results show that the addition of 
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biocompatible polymers does not hinder bone growth and improves the handling 
properties of the materials making them easier to use and implant within a wound site. 
In order to increase the effectiveness of bone graft substitutes, therapeutic drugs 
are often added in impart antimicrobial, osteogenic, or angiogenic characteristics [1, 40].  
By combing both an antibiotic and growth factor, for example, one graft can theoretically 
treat both the infection and bone defect, something that requires several procedures and 
materials using traditional debridements and autografts [1].  Tang et al. impregnated CS 
with gentamicin and liposomal gentamicin, implanted them into a rat tibial defect and 
evaluated the effectiveness at treating a S. aureus infection [62].  All animals treated with 
locally released gentamicin showed no bacteria in their blood at the end of the study, and 
those treated with liposomal gentamicin CS eliminated all the bacteria from the bone as 
well [62].  If PMMA beads had been used, as in McKee et al., they would need to be 
removed before bone grafting could take place so the use of a biodegradable and 
osteoconductive bone graft substitute could reduce the number of procedures necessary to 
treat IBDs [40].  Beardmore et al. further showed that the combination of DBM and 
tobramycin-impregnated CS pellets was osteoinductive, osteoconductive, and able to 
eradicate a S. aureus infection in a goat tibial model [46].  The positive control group of 
antibiotic-impregnated PMMA beads was also able to eliminate the infection but would 
require removal and additional bone grafting to heal the wound [46].  Guelcher et al. 
showed that the addition of an antibiotic to scaffolds containing BMP-2 increased the 
amount of regenerated bone compared to scaffolds with BMP-2 alone in a critically sized 
rat femoral defect model [63].  This is in agreement with knowledge previously discussed 
about the negative effects that bacteria can have on bone healing [18, 20, 21].  Kempen et 
al. investigated the sequential release of vascular endothelial growth factor (VEGF) and 
BMP-2 from a composite scaffold implanted ectopically or orthotopically in rats [64]. 
Scaffolds containing VEGF stimulated significantly higher blood vessel volumes after 8 
weeks in subcutaneous implants than scaffolds containing no growth factors or BMP-2 
alone [64].  When implanted into a critically sized rat femoral defect, scaffolds 
containing BMP-2 stimulated significantly higher bone volumes than control groups, but 
scaffolds containing VEGF and BMP-2 were not statistically different from BMP-2 only 
scaffolds [64]. 
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2.4 Biofilm Infections 
If left untreated, the planktonic bacteria that were implanted into the tissue can 
settle onto a surface and form a biofilm [1, 25, 26].  The bacterial cells can surround 
themselves with a thick matrix of polysaccharides, called the EPS, which hinders the 
diffusion of antimicrobials and host defenses from the surface to the bacterial cells within 
as well as facilitating nutrient intake [19, 65].  The EPS can increase the required amount 
of antibiotic needed to inhibit or kill the bacterial cells by as much as 1,000X which can 
be toxic or unachievable via systemic delivery [25, 29, 31]. Once settled, the biofilm is 
capable of spreading by dispersing small microcolonies that can travel to an uninfected 
region and start a new colony or infection [19].  This is one reason that it is so important 
to eliminate the infection prior to implantation of fixation hardware, since the 
contaminated implant could act as a nidus of infection, spreading the bacteria around the 
body [25, 28, 30].  A chronic infection that is not treated can have a number of negative 
effects on the healing process [30, 31].  An infection which the body has no method of 
removing will cause persistent local inflammation and an increase in host response cells 
at the site of infection [28, 66].  Host cells such as neutrophils, monocytes, and 
macrophages present in greater numbers for a prolonged period of time can cause local 
tissue death through the release of reactive oxygen species and proteolytic enzymes [28, 
66].  Proinflammatory cytokines, such as tumor necrosis factor (TNF)-α, interleukin (IL)-
1, and IL-6 can also be released by bacterial cells, further increasing the inflammatory 
response and negative side effects associated if prolonged [28].  There have also been a 
number of reports of bacterial cells attaching to and invading osteoblasts, protecting them 
from antimicrobial treatments and host defenses [30, 67, 68].  Once internalized the 
bacterial cells can trigger apoptosis in osteoblasts, potentially upsetting the balance of 
bone formation and resorption and negatively affecting the bone healing process [20, 30, 
67].  In the United States, infections associated with joint implants range from 1-3%, 10-
30% for urinary catheters, 1-7% for cardiac pacemakers, and 25-50% for cardiac assist 
devices [69].  Periprosthetic infections occur in approximately 1.5-2.5% of hip and knee 
arthroplasties and a slightly higher 3.2-5.6% of revision surgeries [70]. 
Since many commonly used approaches to treating infections are ineffective at 
eliminating biofilm infections, alternative methods are being investigated.  One method 
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involves inhibiting microbial attachment to implant surfaces by immobilizing 
antimicrobial agents on the surface [28, 71-73].   Kazemzadeh-Narbat et al. showed that 
immobilizing the antimicrobial peptide HHC36 on a CaP coated titanium surface had 
antimicrobial activity against S. aureus and Pseudomonas aeruginosa [51].  One 
significant drawback to this approach is the relatively short timeframe which the coating 
provides antimicrobial effects due to loss of attached peptide [28].  In a study by Vester 
et al. gentamicin was released from a poly(D,L-lactide) (PDLLA) coating on a titanium 
Kirschner-wire (K-wire) in vivo and in vitro [72].  Release of the antibiotic occurred for 
42 days in vitro and 7 days in vivo and the gentamicin loaded coatings were able to 
significantly reduce the adhesion of Staphylococcus epidermidis compared to controls 
[72].  Antoci et al. covalently attached vancomycin to a titanium surface and showed that 
not only did the coating prevent S. aureus attachment but was able to do so after storage 
in buffer solution for 11 months [74].  The coated titanium surfaces were also incubated 
with S. aureus for 1 or 4 weeks and no increase in MIC was seen for vancomycin [74]. 
Methods of extending the release timeframe or preventing release from the implant 
surface at all are necessary in order to eliminate the infection without fear of creating 
resistant bacterial strains [28].  Disrupting the biofilm EPS is another method which has 
potential for the treatment of biofilms since the EPS is the primary defense mechanism 
against the majority of antimicrobial treatments [28, 75].  Once the EPS has been 
disrupted, the bacterial cells should be once again susceptible to normal MIC of 
antibiotics [31].  Some known agents that are capable of disrupting part of the matrix 
structure are dispersin B, lysostaphin, and proteinase K [76-78].  Yet another method 
involves hijacking the biofilms’ own quorum sensing system to initiate dispersal of the 
established biofilm back into a planktonic state, making the bacterial cells more 
susceptible to antimicrobials [78, 79]. 
 
2.5 Significance 
Current treatment for IBDs involves several surgical procedures which increase 
hospital stays, patient costs, and discomfort.  A bone graft substitute that could combine 
all these procedures would be of great benefit to the patient and much research is 
currently being done in this area.  Many of the new methods being investigated do not 
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seek to combine the treatments but to improve upon the first set of procedures to treat the 
infection.  Those that do try to combine two treatments into one procedure often attempt 
to treat both the infection and bone defect at the same time.  The reason that the current 
procedures are separated is to avoid combating the infection while repairing a bone defect 
and has good rationale to be done this way.  The aim of this research was to develop a 
bone graft substitute which was moldable, biodegradable, and capable of maintaining a 
temporal separation in the release of two different drugs for the treatment of infected 
bone defects.  Due to the modular nature of the composite material it would also be 
possible to incorporate different antimicrobials, anti-biofilm agents, or osteogenic drugs 
to tailor the device as needed. 
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Chapter 3 Effects of Composition and Setting Environment on Mechanical 
Properties of a Composite Bone Filler  
This chapter reproduced from an accepted manuscript, “Brown ME, Zou Y, Dziubla TD, 
Puleo DA. Effects of composition and setting environment on mechanical properties of a 
composite bone filler. Journal of Biomedical Materials Research Part A. 2013;101A:973-
80.” 
 
3.1 Introduction 
High energy trauma, resulting from events such as explosions, can cause large 
bony defects that cannot heal spontaneously [3, 13].  Because of the large variability in 
size and location associated with these wounds, treatment can be complicated and require 
multiple procedures [13, 22-24].  Approximately 80% of injuries in Operations Enduring 
Freedom and Iraqi Freedom are the result of explosions [14-16]. 
 The most common method of treatment begins with debridement to remove 
necrotic tissue followed by an autogenous bone graft to replace the missing bone [6, 22]. 
Autografts, which involve harvesting the donor bone from the patient, have been the gold 
standard for bone grafts for over 100 years [6, 24].  Major reasons for their success are 
the incorporation of osteogenic cells and the use of an osteoconductive matrix in the 
grafting material [3].  Harvesting donor bone from the patient also greatly reduces the 
risk of rejection when implanted [3, 35].  Even with all their success, autografts still have 
several drawbacks, including the need for a second surgery to obtain the donor bone and 
donor site morbidity that can cause pain and future complications for the patient [35].  
Allografts are an alternative to autografts that removes the need for the patient to donate 
the bone grafting material and instead obtains it from cadavers [3].  This method does not 
require a second surgery site, but it increases the risk of disease transmission and 
infection [3, 35]. 
 Due to the inherent limitations of traditional bone grafts, substitute bone grafting 
materials have been an area of intense research interest.  Many of these materials are 
designed to be biodegradable, osteoconductive, and provide some mechanical support [3, 
6, 40].  Ceramics, such as calcium sulfate (CS), calcium phosphate cements (CPC), and 
hydroxyapatite (HA), and various polymers, such as polyurethane and poly(lactic-co-
glycolic acid), are being investigated for use as bone graft substitutes [5, 41-43].  CS has 
a long history of clinical use and is biodegradable, biocompatible, and osteoconductive 
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[22, 44, 45].  With the incorporation of antibiotics and growth factors, CS can be used to 
treat infections and stimulate bone formation, further increasing the material’s 
effectiveness in bone regeneration [40, 80, 81].  Along with making more bioactive 
grafting substitutes, there is significant interest in developing moldable or injectable 
systems with the addition of biopolymers that can be more easily applied to a wound and 
can fill the void better than preset materials [5, 42, 45, 57, 82]. 
The present work focused on the development of a composite bone graft 
substitute, composed of CS, microspheres, and a plasticizer, that can eventually be 
modified to deliver biomolecules for the treatment of large bony defects, such as may 
result from explosions.  A key factor in the effectiveness of bone graft fillers is the ability 
to fill the defect completely to prevent soft tissue in-growth; this moldable bone filler will 
be capable of filling any irregularly shaped defect and setting in vivo.  The handling 
properties and moldability of CS were significantly improved by the addition of a 
plasticizer, such as carboxymethylcellulose (CMC) or hyaluronan (HY), which have 
already seen use in human patients for wound healing applications in products, such as 
OP-1 putty and Orthovisc®.  Addition of these biomacromolecules to CS created a 
material that is easy to work and is still capable of setting in vivo.  The effects of 
composition and environment on mechanical properties and degradation time were 
evaluated to determine a balance between setting time and mechanical strength.   
 
3.2 Materials & Methods  
 
3.2.1 General Sample Preparation 
 CS (hemihydrate 98%; Sigma), carboxymethylcellulose (CMC) (medium 
viscosity; Sigma) or hyaluronan (HY) (MW 7.46 x 103, 1.323 x 105, 3.574 x 105, or 2 x 
106 Da; LifeCore Biomedical), gelatin microspheres (Gms), cellulose acetate 
phthalate/Pluronic F-127 microspheres (CAPPms), gentamicin (Sigma), and vancomycin 
(Sigma).  Sample compositions used in the various studies can be seen in Table 3.1.  A 
series of different compositions were investigated as the composite material was 
continuing in development, each experiment providing valuable information for the 
experiments to follow. 
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Table 3.1: Formulations of moldable bone filler used in different experiments expressed 
as weight percentages. 
  Component (wt. %)  
Sample Set CS CMC HY CAPP Gms Gentamicin Vancomycin  
Setting Environment 90 5 0 2.5 2.5 0 0 
Composition Effects on Mech. 
Strength over Time 
85 5 0 5 5 0 0 
80 10 0 5 5 0 0 
100 0 0 0 0 0 0 
Polymer Comparison 
95 0 5 0 0 0 0 
95 5 0 0 0 0 0 
Mass Loss  85 5 0 5 5 0 0 
Set Time  
87 5 0 0 5 1.5 1.5 
87 0 5 0 5 1.5 1.5 
95 0 5 0 0 0 0 
 
Microsphere preparation is detailed in the following section.  The relative 
amounts of each component were varied to determine the effects while maintaining a 
strong, moldable material.  All components were dry mixed by hand prior to addition of 
deionized water.  The amount of water required varied (usually between 300-600 µl/g) 
depending on the relative amounts of components in the composite, and samples were 
fabricated such that a non-sticky, moldable material was formed.  The moldable filler was 
then packed into cylindrical Delrin molds (6.5 deep x 3.2 mm diameter), and samples 
were removed once they could be pushed out without deformation, which took between 
10-20 minutes depending on the composition.  Pictures demonstrating the moldable 
nature of the filler can be seen in Figure 3.1. 
 
15 
 
 
Figure 3.1 Schematic image of the cylindrical bone filler samples used for mechanical 
testing (top); plasticizers, ‘CMC or HY’, were dispersed throughout the CS matrix to 
improve the handling properties of the CS.  A picture of actual bone filler samples 
(bottom left) and a demonstration of the moldable nature of the CS composite material 
(bottom right). 
 
3.2.2 Microsphere Preparation 
Gelatin microspheres were prepared using methods adapted from Zou et al [83, 
84].  A solution of 10% gelatin in deionized of water was added to 200mL of stirring 
olive oil (40°C) in a drop-wise manner.  The mixture was then chilled to 10 °C with 
stirring for 30 min before the addition of 60mL of chilled (4 °C) acetone for an hour with 
continuous stirring.  The solution was centrifuged (123 g force for 5 minutes) before 
microspheres were collected by filtration (11 µm; Whatman).  The microspheres were 
then crosslinked by being placed in stirring 20mM glutaraldehyde for 12 hours at 4°C.  
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The crosslinked microspheres were collected and immersed in 50mM glycine solution for 
2 hours to block residual aldehyde groups.   
Cellulose acetate phthalate/Pluronic F-127 microspheres were prepared by first 
dissolving cellulose acetate phthalate (CAP) and Pluronic in acetone at a weight ratio of a 
2.33:1 (CAP: Pluronic) while shaking [85].  This emulsion was added rapidly into 4 
volumes of corn oil and sonicated (25W) for 5 seconds.  The CAP/oil solution was then 
added to 5.3 volumes deionized water along with 0.5 volume of Triton X-100 solution; 
the combined solution was then homogenized at 1509.2 g force for 5 minutes.  The 
resulting suspension was centrifuged at 277 g force for 5 minutes to separate the CAPP 
microspheres, and the oil and water phases were removed by aspiration.     
 Both types of microspheres were lyophilized for 24 hours prior to use.  
Characterization of microspheres was reported previously, and microscopic observations 
showed their diameter to range from 70-150 µm and 70-110 µm for gelatin and CAP-
Pluronic, respectively [84, 86].  In future work, these microspheres could be loaded with 
bioactive drugs for the treatment of infected bony defects. 
 
3.2.3 Mechanical Properties of Composite Material 
In order to test the properties of set composites with HY compared to CMC, 
mechanical testing was performed on samples 10-20min after fabrication.  Samples were 
removed from the mold as soon as possible and allowed to air dry for 10min, at which 
point compression testing was performed.  The aim of this part of the study was to 
determine how quickly the different compositions were able to set. 
 
3.2.4 Setting Environment 
Once bone filler samples were removed from the mold, they were placed in one of 
three environments to set: 1) oven at 40°C , 2) a fully humidified cell culture incubator at 
37°C, or 3) immersion in 1.5 or 3 mL, phosphate-buffered saline (PBS), pH 7.4  at 37°C.  
Samples were dried in an oven for comparison against other preset calcium phosphate or 
calcium sulfate bone grafting materials/cements.  The cell culture incubator and 
immersion in PBS were examined in order to simulate two extremes of the simulated in 
vivo environment.  Different volumes of PBS were used in order to determine what effect 
17 
 
the surface area (sample) to volume (PBS) ratio had on the degradation rate of the bone 
filler samples.  
 
3.2.5 Mechanical Properties and Degradation 
Compression testing was performed on cylindrical samples using a Bose ELF 
3300 mechanical testing system.  Samples were removed from their respective setting 
environment, or the mold in the case of the set time experiments, and tested immediately 
afterwards.  Load was applied at 5 N/sec until failure, and the elastic modulus (M) and 
ultimate compressive strength (UCS) were calculated.   
Non-destructive degradation studies were performed by placing composite 
samples in either 1.5 or 3mL static PBS at 37°C.  The solution was changed every three 
days, and at each time-point three samples were removed, dried for 24 hours at 40 °C, 
and then weighed.  Volumes of 1.5 or 3 ml of PBS were used because calculations based 
on solubility of CS indicated the volumes would maintain sink conditions while being 
small enough to enable detection of released drugs in future studies.  The solubility of CS 
is approximately 2.4mg/ml H2O.  In the case of the deg. study with 1.5ml PBS, the 
samples would have needed to degrade 42% over the 3 day period between samplings to 
reach the solubility limit of CS.  Pilot study data (not shown) showed that samples 
reached steady state mass after 4 hours when dried at 40 °C.  The initial and final weights 
after degradation were then used to determine the percent mass loss for each sample.   
 
3.2.6 Statistical Analysis 
One-way and two-way analysis of variance (ANOVA) was performed using 
Prism (GraphPad). Statistical analysis was determined at p values less than 0.05.  
Bonferroni’s post-hoc test was performed as needed.  Because certain testing groups were 
small, normality tests and data skew was used in order to test the validity of using 
ANOVA statistical methods.  
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3.3 Results 
 
3.3.1 Initial Mechanical Properties of Composite Material 
Bone filler samples that contained HY instead of CMC had significantly (p < 
0.05) better mechanical properties when tested shortly after mixing (Figure 3.2).  The 
samples containing CMC were still very moldable even after testing, which resulted in 
low mechanical stiffness of the cylinders.  Samples that contained microspheres showed 
inferior mechanical strength to those containing CS and HY alone.   
 
Figure 3.2: Effect of composition on initial mechanical properties of composites.  All 
samples were evaluated within 20 minutes of fabrication, and 1.323 x105 Da HY was 
used in all samples containing HY. (Data are mean ± SD, n=6, 6, 5, or 5 for the groups 
evaluated, respectively; p<0.001, *p<0.01, **p<0.001). 
The type of plasticizer used in the composite influenced the mechanical 
properties, but no significant difference was seen between the different MW HY samples 
(Figure 3.3).  Samples containing Low and Med-low MW HY had compressive moduli 
ranging from 1400-1500 MPa, significantly higher (p < 0.05) than samples containing 
CMC with an average compressive modulus of 550 MPa. 
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Figure 3.3: Effect of type of biopolymer on mechanical properties of CS with 5 wt% of 
CMC or varying MW hyaluronan. , Low=7.46 x 103, Med low=1.32 x 105, Med 
high=3.57 x105, High=2.0 x 106 Da. (Data are mean ± SD, n=11, 11, 5, 5, and 7 for the 
groups evaluated, respectively; *p<0.05, **p<0.01). 
 
3.3.2 Setting Environment 
The elastic modulus of the bone filler composites as well as CS controls under 
different setting conditions can be seen in Figure 3.4.   Composite samples placed in wet 
environments, such as a cell culture incubator or submerged in PBS, showed significantly 
lower (p < 0.05) mechanical properties after 24 hours when compared to those dried in 
air.  An UCS of 0.86 MPa and compressive modulus of 42 MPa was seen in samples 
placed in an incubator compared to 11 MPa and 453 MPa seen in samples air dried.  
Samples that were placed directly into PBS retained their cylindrical shape but did not 
fully set and were unable to be mechanically tested.   
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Figure 3.4: Effect of setting environment on compressive modulus.  90/5/2.5/2.5 PBS set 
was not tested because the samples were too fragile to even remove from the PBS 
without deforming or breaking. (Data are mean ± SD, n=4, 4, 11, 8, 6, and 4 for the 
groups evaluated, respectively; One-way ANOVA for compressive modulus and UCS p 
< 0.0001) 
 
3.3.3 Mechanical Properties over Time and Degradation 
The relative amounts of the composite material components were shown to have a 
significant (p < 0.0001) effect on the mechanical properties (Figure 3.5).  Addition of 
larger amounts of plasticizer or microspheres to the composites resulted in lower 
mechanical properties over time (p < 0.0001).  All three compositions became stronger 
over the first few days as the CS was able to fully set in the humid environment.   
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Figure 3.5: Effect of composition on modulus of the moldable bone filler dried in a 
humidified environment. (Data are mean ± SD, n=4; Two-Way ANOVA p < 0.0005). 
The type of plasticizer used, either CMC or HY, did not have any significant 
effect on the degradation rate of the bone filler composite (Figure 3.6).  The time until 
complete degradation was approximately 18 days for both polymers examined.  The 
samples began degrading by erosion, getting smaller throughout the 18 days; however 
some samples began to fragment towards the end of the degradation period.  The ratio of 
sample surface area to volume of PBS in which they were incubated (SA/vol.), however, 
seemed to have a slight effect on the degradation profile by increasing the degradation 
rate with a higher SA/vol. ratio, but the results were not significant.   
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Figure 3.6: Effect of SA/Vol. ratio on degradation of composites containing either 5 wt% 
of CMC or HY (1.323 x 105 Da).  Samples in 3 and 1.5 mL PBS had SA/vol. ratios of 21. 
8m and 43.6 mm2/mL, respectively; no significant difference was seen between the two 
SA/vol. ratios. (Data are mean ± SD, n=3). 
 
3.4 Discussion 
 
3.4.1 CS as a Bone Filler 
CS has been used in many different forms as a bone graft substitute, such as 
injectable treatments, moldable putties, or as preset pellets [5, 22, 59].  CS-based 
materials have many useful properties for bone regeneration, such as being 
osteoconductive, biodegradable, and biocompatible [22, 45].  CS paste alone is very 
sticky and sets quickly which makes it difficult to work with in a clinical setting, the 
addition of a plasticizing polymer to the CS matrix makes the material injectable or 
moldable and generally increases the working time [5, 45, 57].  While CS has many 
useful natural properties, it is not osteoinductive, a key factor in the success of a bone 
grafting material in large defects [3].  CS based materials also do not posses any inherent 
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antimicrobial properties and require the same repeated debridement/irrigation procedures 
as traditional grafts [22, 44].  Antibiotics and osteogenic molecules can be added to CS in 
order to create a material that is antibacterial, osteoinductive, and osteoconductive [40, 
45, 48].  In the present study, a moldable, biocompatible, and biodegradable bone filler 
material was created that could be loaded with different bioactive agents.  The 
degradation and mechanical strength were shown to be tailorable depending on the ratio 
of components within the composite, and the properties also depended considerably on 
the environmental conditions around the samples as discussed below.  While this 
composite material is not within the range needed for a fully weight-bearing material 
(addressed further in the next section), it is strong enough to be used in a similar manner 
as traditional bone grafts. 
 
3.4.2 Compositional Effects on Mechanical Properties 
 Much of the recent research into bone filler substitutes has examined composite 
materials that are easier to handle and apply clinically [5, 45, 60].  These materials are 
often created by the addition of a plasticizing agent that can make the composite 
injectable or moldable [5, 59].  Antibiotics or growth factors are often included in these 
composite bone fillers in order to increase the therapeutic effects by fighting infections or 
actively promoting the growth of bone [47, 48, 62, 87, 88].  The ability to load both 
antibiotics and osteogenic molecules into the same moldable grafting material is not 
commonly done and creates a bone grafting substitute that has larger therapeutic 
applications.     
The mechanical properties of bone vary considerably depending on the type of 
bone, the location of the bone, and the health of the patient [3].  The difference in 
mechanical properties between cortical and cancellous bone is very large, with the 
compressive modulus of cortical bone ranging from 7-25 GPa while cancellous bone 
ranges from 0.1-1 GPa [3, 59].  The ultimate compressive strength of cortical bone and 
cancellous bone ranges from 50-150 and less than 1 MPa, respectively [3].  Many bone 
filler materials aim to have similar mechanical properties to the bone they temporarily 
replace in order to reduce complications with surrounding bone and make the materials 
more load-bearing [3, 59]  Several injectable CPC and CS systems have compressive 
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moduli ranging from 1-165 MPa [59, 89].  There are also other moldable systems that use 
either a polymer or microspheres to create a more workable putty or paste for placement 
into irregularly shaped defects [42, 57].  These materials had diametrical tensile strengths 
ranging from 6-10 MPa [42, 57].  The moldable bone filler material developed in this 
study had compressive moduli ranging from 10-350 MPa and UCS ranging from 5-20 
MPa, depending on the formulation and setting conditions.  The mechanical strength of 
the composite material is significantly less than that of cortical bone but near that of 
cancellous bone. 
Using HY instead of CMC in the composite material resulted in a stronger 
material and a faster setting time.  This was likely due to the increased number of 
hydroxyl groups present on the HY allowing it to imbibe large quantities of water, much 
like it does in cartilage [90].  The MW of the CMC used was 2.5 x 105 Da, which is 
slightly larger than that of the 1.3 x 105 Da HY that was chosen for continued use.  Since 
the MW of these two polymers is similar, it likely was not much of a factor in their water 
retention properties.  The CMC used had fewer hydroxyl groups available to bind with 
water in part due to substitution with carboxymethyl groups during its synthesis.  By 
retaining more water than CMC, and thereby decreasing the amount of free water for CS 
dissolution, the HY biopolymer makes it easier for solution super-saturation and 
conversion to CS dihydrate, which resulted in faster setting.  Because the present material 
is intended to be implanted in a moldable (i.e., not set/hardened) state, the working time 
available to the surgeon after mixing is clinically important.  A setting time of 20 minutes 
was used as a characterization bench mark, because setting times less than this may not 
provide enough time to implant the material properly.  Similarly, setting times greatly 
exceeding 20 minutes will likely plastically deform in situ and degrade more quickly in 
the wound site.   
The strength of the bone filler material was directly related to the amount of CS.  
More CS present within a fixed volume of water allowed the conversion from 
hemihydrate to dihydrate to happen more quickly because the solution can more readily 
become super-saturated with dihydrate.  This increased amount of dihydrate form of CS 
caused the resulting material to possess superior mechanical properties.  All three 
compositions became stronger over the first couple of days when stored in the cell culture 
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incubator at 100% humidity.  This is likely due to the CS setting process being slowed 
down by the large amount of water in the air. Since the major structural component of the 
composites was not fully set during the first several testing points the bone filler samples 
would be weaker than fully set samples.  The average compressive modulus of the 90-5-
2.5-2.5 samples stored in the incubator at day 7 is approximately 360 MPa, similar to the 
air dried 90-5-2.5-2.5 samples which had an average compressive modulus around 400 
MPa.  It is likely that after 7 days the samples were fully set and the reason for the 
decrease in mechanical strength at day 14 was due to the excess humidity in the air 
weakening the CS matrix [91].  The amount of water added to the dry components to 
make the filler ranged from 300-600 µl/g and was chosen based on the handling 
properties of the resulting putty.  A lower content of microspheres or plasticizer caused 
an increase in the mechanical properties of the composite filler due to the decreased water 
retention, increased amount of CS, and in the case of microspheres, a decreased number 
of stress concentrators.  The gelatin microspheres are very hydrophilic as are the 
plasticizers used to create a moldable material; this added water retention would slow 
down the conversion of CS hemihydrate to CS dihydrate in a similar manner as described 
above for the setting conditions.  CAPP microspheres would not contribute much to water 
retention since they are surface-eroding and do not absorb much water as they degrade.   
 
3.4.3 Setting Conditions 
The conditions in which the CS bone filler was set had a significant effect on the 
mechanical properties of the composite, which were directly related to the amount of 
water in the system.  The additional water that the samples were exposed to in the 
humidified cell culture incubator or when immersed in PBS did not allow the material to 
ever fully set.  The α-hemihydrate form of CS normally forms a stronger, denser, 
dihydrate material when dried [92].  During this reaction, the hemihydrate form of CS is 
converted into a dihydrate form; this reaction is driven by the solution becoming super-
saturated with the dihydrate form followed by nucleation and crystal growth [45].  Once 
the solution is no longer saturated, more of the hemihydrate form can dissolve and super-
saturate the solution again.  With excess amounts of water in the system, it is difficult for 
the solution to become supersaturated and begin nucleation and crystal growth.  It has 
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also been shown that the addition of polymers or presence of biological molecules, such 
as proteins, can slow down the setting time and make it difficult for the material to set in 
vivo [93].  If the material is unable to fully set in vivo as intended the mechanical integrity 
and therapeutic effects may be compromised. 
 In clinical applications, the actual setting environment will be likely somewhere 
between full immersion in solution and the cell culture incubator.  Immersion in a fluid is 
the most common environment for investigating a bone grafting substitute’s drug release 
and degradation profiles [47, 59, 60, 94, 95].  In vivo conditions would be very difficult 
to replicate in vitro since many different factors must be considered.  The bone filler 
composite will be loosely confined within the wound site and subjected to a small but 
continuously exchanged fluid flow from the body along with wound healing cells and 
bacteria.  Immediately upon implantation within the body, proteins will begin to adsorb 
onto the surface of the material [96].  These adsorbed proteins can become entangled in 
the crystal structure and slow down the set time or weaken the mechanical strength of the 
material [59, 89].  All of these factors will contribute to the degradation and function of 
the bone filler and should be considered carefully when planning in vitro experiments. 
 The degradation profiles showed the small filler samples degrading over the 
course of around 18 days.  Although the ideal time for a grafting material to be present in 
a defect site is unknown, larger samples appropriate for (pre)clinical applications would 
take longer to degrade.  Interestingly, the percentage mass remaining did not go all the 
way to zero.  One reason for this observation was that at later time points in the 
experiment, the samples began to break apart considerably, and accurate mass 
measurements could not be taken, so the samples were considered completely degraded.  
Furthermore, Mamidwar et al. showed that a calcium phosphate lattice forms as calcium 
sulfate degrades, and this insoluble mineral phase will prevent the mass from reaching 
zero [97].  The degradation profiles varied with the surface area to volume ratio of the 
sample and the amount of solution they were immersed in; this was likely due to 
saturation/solubility effects of the PBS.  Once the solution containing the sample became 
saturated, dissolution of the components would slow considerably.  The sample surface 
area to supernatant volume ratio should affect the degradation rate by determining how 
quickly the solution becomes saturated, and generally the solution should be at high 
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enough volumes and changed frequently enough to remain at sink conditions to best 
understand the degradation and release mechanisms of a biomaterial.   
3.4.4 Moldable Systems 
 Moldable bone graft substitutes have the advantages of being easier to handle 
during implantation than pastes as well as having the ability to conform to any irregularly 
shaped defect, thereby minimizing the space between the native tissue and implanted 
material.  These systems also remove the need for a preset material and allow for a better 
fit of the implanted graft and host tissue.  Various types of biocompatible polymers have 
been used in order to create moldable bone graft substitute systems, such as CMC, 
sodium alginate, and PLGA microspheres [5, 42, 45, 57].  When a moldable putty was 
created instead of a more viscous paste in these other systems, the degradation rate was 
comparable, while the mechanical properties were lower.  In a study by Habraken et al., 
an injectable CPC was created using gelatin microspheres to create a workable paste and 
to create macropores for the ingrowth of tissue [82].  Simon et al. created a composite 
bone graft paste by combining poly(lactide-co-glycolide) (PLGA) microspheres with a 
CPC, which resulted in a material that was mechanically weaker than CPC alone but 
contained up to 18% micropores that could allow ingrowth of tissue [42].  This paste still 
suffers from the slow degradation rate of CPCs; the material showed little signs of 
degradation after three months, even after the outermost PLGA particles had degraded 
leaving micropores [42].  In a manner similar to the moldable bone filler material 
presented here, it would be possible to tune the degradation and mechanical properties of 
these moldable systems by changing the base components and ratio of components. 
 
3.5 Conclusions 
A moldable, biocompatible, and biodegradable bone grafting substitute was 
developed using CS, microspheres, and a plasticizer.  The mechanical strength and 
setting time of the filler material can be tailored by altering the ratio of various 
components or the type of plasticizer used.  Adding any components to the CS, such as 
biopolymer or eventually antibiotics or biomolecules, increases its functionality but 
decreases its mechanical strength and ability to set in harsh environments.  The plasticizer 
HY was shown to create a stronger composite material than those using CMC while still 
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retaining its moldability and biocompatible nature.  The samples degraded in a linear 
fashion over the course of 18-20 days in PBS, and samples containing HY instead of 
CMC showed a slightly slower initial degradation.  In addition to possessing many of the 
desired mechanical properties of bone graft substitutes, the material can be loaded with 
bioactive molecules.  The present composite filler will be further explored as an 
alternative to traditional bone grafting treatments. 
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Chapter 4 Release of Bioactive Molecules from a Moldable Calcium Sulfate Bone 
Graft Substitute 
This chapter reproduced from an accepted manuscript, “Matthew E. Brown, Yuan Zou, 
R. Peyyala, Thomas Dziubla, and David A. Puleo. Temporal Separation in the Release of 
Bioactive Molecules from a Moldable Calcium Sulfate Bone Graft Substitute, Current 
Drug Delivery, 2014, in review.” 
 
4.1 Introduction 
Open bone defects are a challenge to manage clinically because of the high 
variability in size, shape, and location of the wounds [13, 22-24].  The likelihood of 
infection and the multitude of required procedures further increases the complexity of 
treatment [13, 22-24].  Traditional standard of care for an infected bony defect (IBD) 
includes repeated debridement and 4-6 weeks of systemic antibiotics until the wound is 
free of infection, followed by fixation and grafting with donor bone [18, 19, 22, 98].  
While autografts are the gold standard for repairing large bone defects, they have several 
drawbacks, such as limited supply of and the need for a second surgery, circumvented by 
synthetic bone graft substitutes [24, 35].  Autografts have remained the preferred 
treatment for bone defects, primarily due to the presence of osteogenic cells within the 
donor tissue, which will stimulate bone healing in the defect [3, 24].  Osteogenic drugs 
can be incorporated into synthetic bone grafting materials, however, to enhance their 
effectiveness and make them more comparable to autografts [13, 87]. These synthetic 
materials are often formed from calcium sulfate (CS), poly(methyl methacrylate) 
(PMMA), calcium phosphate (CaP), tricalcium phosphate (TCP), hydroxyapatite (HA), 
or biocompatible polymers [23, 40, 98-101]. 
A major reason why large IBDs are so difficult to treat is that the extent and type 
of infection can vary widely, and the presence of the bacteria delays healing [19, 23, 30].  
In the worst cases, planktonic bacteria in the wound attach themselves to surfaces and 
form a biofilm, which is a special arrangement of bacterial cells that behave as a 
community and secrete a polymeric coating [19, 30].  This coating acts as a barrier to 
most antimicrobials, rendering them ineffective at safe systemic concentrations [28].  By 
delivering antibiotics locally, much higher concentrations can be achieved at the site of 
interest than would be possible via systemic delivery [98, 102, 103].   
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 In clinical practice for treating IBDs, the first goal is to clear the infection before 
bone repair is even attempted [6, 22].  There are two primary reasons for this separation: 
one is to limit the foreign surfaces within the defect that could act as niduses for bacterial 
colonization, and the other is to avoid trying to heal bone in such a harsh environment 
[23, 104].  The infected milieu will cause decreases in the local oxygen content and pH, 
as well as promote chronic inflammation [30].  Bacteria also contribute to bone 
resorption, which would counteract any osteogenic treatment and result in less effective 
healing [30].     
The present research focused on achieving a temporal separation between 
antimicrobial and osteogenic drugs released from a previously developed synthetic bone 
grafting material [105]. This separation will mimic clinical practice and allow time for 
the antimicrobial to treat the infection prior to the osteogenic drug stimulating bone 
healing.  A two-part composite system composed primarily of CS was developed that 
utilized a moldable outer shell, which provided the prolonged release of the antimicrobial 
drug, around a solid core that afforded delayed release of the osteogenic drug.  
Hyaluronic acid (HY) was used to make the CS shell moldable and was chosen based on 
previous results and because it is already being used in FDA-approved wound healing 
applications (OrthoviscVR) [105].  Two antibiotics, vancomycin and gentamicin, were 
initially used to provide a material capable of combating Gram-positive and Gram-
negative bacteria.  This two-part method combines the advantages of moldable and pre-
set bone filler systems, allowing the material to conform to irregular defects while 
maintaining extended release of bioactive drugs.  The shell/core method was evaluated 
for achieving temporal separation of drug release profiles as well as bioactivity of the 
released antimicrobial on Staphylococcus aureus (S. aureus) bacteria.   
 
4.2 Materials & Methods 
 
4.2.1 Poly(lactic-co-glycolic acid) (PLGA) Microsphere Fabrication 
PLGA microspheres (PLGAms) were fabricated using a double emulsion 
technique (W/O/W).  The oil phase consisted of 13% PLGA (w/v) (50:50 L:G, 0.55-0.75 
I.V.; Durect Corp.) dissolved in dichloromethane (DCM).  The first emulsion was created 
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by adding 0.11 vol% of phosphate-buffered saline (PBS), either blank or drug-loaded 
(100 mg/ml vancomycin), to the PLGA-DCM solution and sonicating for 10 seconds at 
25 W.  This W1/O emulsion was added to 800 ml of deionized water (containing 1% 
polyvinyl alcohol and 4% NaCl) in a dropwise manner and then homogenized at 2000 
rpm for 3 minutes to create the second emulsion.  The resulting suspension of 
microspheres was stirred overnight at 600 rpm to evaporate the solvent.  The 
microspheres were collected by centrifugation and washed using deionized water before 
being frozen and lyophilized. The mass of drug in microspheres was obtained by first 
dissolving 10 mg of microspheres in 1 ml DCM, mixing with 1 ml PBS, and centrifuging 
at 123g for 5 minutes.  The supernatant was analyzed by measuring the absorbance at 280 
nm (Powerwave HT, Biotek), with subsequent comparison to known standards.  The drug 
loading and encapsulation efficiency were calculated as: 
% 𝐷𝑟𝑢𝑔 𝐿𝑜𝑎𝑑𝑖𝑛𝑔 = (
𝑀𝑎𝑠𝑠 𝑜𝑓 𝐷𝑟𝑢𝑔 𝑖𝑛 𝑀𝑖𝑐𝑟𝑜𝑠𝑝ℎ𝑒𝑟𝑒𝑠
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑀𝑖𝑐𝑟𝑜𝑠𝑝ℎ𝑒𝑟𝑒𝑠
)  × 100 
% 𝐸𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 = (
% 𝐷𝑟𝑢𝑔 𝐿𝑜𝑎𝑑𝑖𝑛𝑔
% 𝑇ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝐷𝑟𝑢𝑔 𝐿𝑜𝑎𝑑𝑖𝑛𝑔
)  × 100 
 
4.2.2 General Sample Preparation 
 The following materials were used in fabricating the composite bone filler 
samples:  CS (98% hemihydrate; Sigma), hyaluronan (HY) (MW 1.323 x 105 Da; 
LifeCore Biomedical), simvastatin (Haorui Pharma-Chem), gentamicin (Sigma), and 
vancomycin (Sigma-Aldrich).  Compositions used for the core and shell components in 
the various studies can be seen in Tables 4.1 and 4.2.  The “blank” formulations were 
used for background correction in the drug analyses and are not shown in the subsequent 
figures. 
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Table 4.1: Composition of the shells and cores of free vancomycin samples (expressed in 
wt%). X/Y: X=drug component of shell, Y=drug component of core. V=vancomycin, 
G=gentamicin, and S=simvastatin. 
Sample  Layer % CS % HY % Sim % Vanc. % Gent. 
V+G/5S 
Shell 87 10 0 1.5 1.5 
Core 90 5 5 0 0 
V+G+2.5S/2.5S 
Shell 84.5 10 2.5 1.5 1.5 
Core 92.5 5 2.5 0 0 
 
Table 4.2: Composition of the shells and cores of PLGA microsphere samples (expressed 
in wt%). X/Y: X=drug component of shell, Y=drug component of core. V=vancomycin, 
S=simvastatin, B=blank, N=no shell present. 
Sample  Layer % CS % HY % Sim 
% Vanc 
PLGAms 
% Blank 
PLGAms 
V/S 
Shell 75 10 0 15 0 
Core 90 5 5 0 0 
V/B 
Shell 75 10 0 15 0 
Core 95 5 0 0 0 
B/S 
Shell 75 10 0 0 15 
Core 90 5 5 0  
B/B 
Shell 75 10 0 0 15 
Core 95 5 0 0 0 
N/S 
Shell No shell present  
Core 90 5 5 0 0 
N/B 
Shell No shell present  
Core 95 5 0 0 0 
The shell materials listed for each composition were mixed thoroughly before the 
addition of 100-125 µl deionized water; the volume of water was adjusted to keep the 
consistency of the moldable filler uniform.  Shell consistency after mixing was similar to 
a moldable dough that was not sticky and could be rolled or formed into a desired shape 
as described previously [105]. Core pieces were prepared by loading 300 mg of materials 
into a cylindrical Delrin mold (6.5 mm deep x 3.2 mm diameter) followed by drying at 40 
°C overnight.  The moldable shells, also composed of 300 mg total material, were 
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wrapped around the pre-dried cores and used immediately for experiments to ensure the 
composite remained moldable (Figure 4.1).  
 
Figure 4.1: A) Schematic representation of the shell-core structure of bone filler samples. 
Note:  illustration not to scale.  B) Image showing cross-section of a bone filler sample in 
which the shell material had been stained blue. 
 
4.2.3 Release Profiles 
Release studies were performed by incubating the two-layered samples in 4 ml of 
PBS at 37°C with gentle shaking.  The solution was changed every day for the free 
antibiotic samples and every three days for samples containing PLGAms.  For 
comparison, 30 mg of vancomycin-loaded PLGA microspheres alone were shaken in 4 
ml of PBS at 37°C, and the solution was changed every day for four days and every third 
day afterwards.  The collected supernatants were frozen until analysis.  Groups with 
comparable release results not shown to enhance readability of figures. 
Vancomycin concentrations were determined by measuring absorbance at 280 
nm, and gentamicin concentrations were determined by reaction of ο-phthaldialdehyde 
and measuring absorbance at 333 nm [106].   Simvastatin was measured by high-
performance liquid chromatography (HPLC; Hitachi Primaide, C18 column, 5 µm).  The 
mobile phase consisted of 70% acetonitrile and 30% water (containing 1% trifluoroacetic 
acid), and absorbance was read at 240 nm.  Before analysis, all supernatants were filtered 
(0.45 µm) before the addition of 0.25 mg/ml ethylenediaminetetraacetic acid (EDTA) to 
prevent precipitation of calcium.   
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4.2.4 Antibacterial Bioactivity 
To test the effectiveness of antibiotic released from the bone filler samples, a 
traditional Kirby-Bauer (KB) study was performed as well as a modified KB study in 
which the entire samples were used.  For the conventional KB study, 5 µl of release 
supernatant were soaked into a filter paper disc and placed on a blood agar plate seeded 
with S. aureus (ATCC 25923; McFarland standard 0.5).  The resulting zone of inhibition 
(ZOI) was measured after incubating for 24 hours.  In the modified KB study, the plate 
was seeded with the same amount of S. aureus, but the entire core-shell bone filler 
sample was placed directly on the agar (Figure 4.2) for 24 hours before the ZOI was 
measured.  The sample was then transferred to a newly seeded agar plate and again 
incubated for 24 hours, after which the ZOI was measured and the process repeated until 
no inhibition of bacterial growth was seen.  The total area of inhibition was measured 
using NIH ImageJ.   
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Figure 4.2: Setup of the modified Kirby-Bauer study in which an entire shell/core bone 
filler sample was tested instead of filter paper loaded with release supernatant. 
 
4.2.5 Statistical Analysis 
One- and two-way analysis of variance (ANOVA) was performed using Prism 
software (GraphPad). Statistical significance was determined at p values less than 0.05.  
Tukey’s post-hoc test was performed as needed.  
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4.3 Results 
 
4.3.1 Release Profiles 
Release profiles for vancomycin and gentamicin loaded directly into the CS 
matrix can be seen in Figure 4.3.  Around 80-90% of the drug was released within the 
first day, and the remaining drug was slowly released over the next two to three days.  
Instantaneous concentrations were as high as 330 µg/ml at day 1 but dropped to near 0 
µg/ml by day 3.  There was no statistical difference in release concentrations for the two 
antibiotics, but a significant effect with respect to concentration and time was shown (p < 
0.0001).  Full release results can be seen in Supplemental 1.  Vancomycin release profiles 
from PLGA microspheres alone and from PLGA microspheres within the composite bone 
filler material can be seen in Figure 4.4.  PLGA microspheres had a 6% vancomycin 
loading and a 17% encapsulation efficiency.  A 33% smaller burst release compared to 
free loaded vancomycin was seen during the first day, and drug was slowly released from 
the microspheres embedded within the bone filler material over the course of the next six 
weeks. The concentration of vancomycin stayed above 10 µg/ml for the first 30 days and 
above 1 µg/ml throughout the full course of the material’s degradation.  The profile for 
release of simvastatin from the bone filler can be seen in Figure 4.4.  When simvastatin 
was loaded into the pre-dried core with the shell acting as a barrier, release was delayed 
for around 12 days, after which the drug was slowly released for the next four weeks.  
Cumulative release profiles for vancomycin loaded into PLGAms alone, vancomycin 
loaded into the bone filler samples, and simvastatin can be seen in Figure 4.4B.  
Statistical analysis of both the instantaneous and cumulative release profiles showed 
significant effects (p < 0.0001) for the drug type, time interval, and interaction between 
drug and time. 
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Figure 4.3: Release profiles for gentamicin and vancomycin loaded directly into the CS 
matrix (V+G/5S from Table 1).  Data are mean ±SEM, n=4. 
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Figure 4.4: A) Instantaneous and B) cumulative release profiles for PLGA microspheres 
alone (PLGAms) and the two-layered bone filler.  Sample composition was V/S as seen 
in Table 2.  Data are mean ± SEM n=5. 
4.3.2 Antibacterial Bioactivity 
 Bioactivity of the released antibiotic against S. aureus can be seen in Figure 4.5.  
The traditional Kirby-Bauer results showed inhibition of bacterial growth from the 
supernatant for almost 1 week.  When composite bone filler samples were used instead of 
supernatant-soaked filter paper, the total area of inhibition was approximately six times 
larger.  The area of inhibition for complete samples was not only significantly larger than 
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that for the supernatant KB, but antimicrobial activity lasted for at least two weeks.  
There was no statistical difference seen between the V+G/2.5S and V+G+2.5S/2.5S 
groups through 12 days.  The solid line in Figure 4.5 represents the ZOI measured in a 
traditional KB study with 100 µg/ml vancomycin for comparison.  Supernatants alone 
maintained the same ZOI for one day while the composite bone fillers maintained a 
comparable ZOI to the 100 µg/ml vancomycin control for around 12 days.  Two-way 
ANOVA of the area of inhibition results for V+G/2.5S, V+G+2.5S/2.5S, and the 
supernatant KB showed statistically significant differences with respect to sample type, 
time, and the interaction between the sample type and time (p < 0.0001).   
 
Figure 4.5: Results from the traditional Kirby-Bauer experiment (supernatant KB, 
V+G+2.5S/2.5S) and the modified KB study (V+G/2.5S and V+G+2.5S/2.5S).  Solid line 
represents the area of inhibition for 100 µg/ml vancomycin for reference.  Data are mean 
±SEM, n=4-12. 
 
4.4 Discussion 
The current clinical treatment for IBDs requires extensive debridement until the 
infection has been eliminated followed by bone grafting [6, 22].  This approach, which 
requires multiple procedures, is needed because implanting the bone graft in the presence 
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of an infection greatly reduces its potential for success, and the graft itself can become a 
site for bacterial attachment [26, 107].  Along with debridement, it is common for 
systemic antibiotics to be administered for 4-6 weeks to ensure the infection has been 
eliminated [10, 44, 66, 98].  This long treatment time is necessary due to the inefficiency 
of the delivery method at achieving effective concentrations at the infected site [108].  
With localized delivery, much higher doses of the required antibiotics can be obtained 
without the danger of toxicity that can be associated with systemic delivery [98, 108].  
Local delivery of antibiotics also avoids first pass metabolism, which is a major problem 
for oral delivery, and can result in a larger amount of the administered drug reaching the 
infected site than does IV administration [108].  While no standard timeframe has been 
established for localized treatment of infections, it is generally agreed upon that 
antibiotics should remain above minimum inhibitory concentration (MIC) values for as 
long as possible, usually 4-6 weeks, to increase the likelihood of eliminating the infection 
and reducing resistance development [10, 44, 63, 66, 98].     
Vancomycin loaded directly into the CS shell of the composite bone filler 
diffused into solution very quickly, with the majority of the payload being released over 
the course of the first two days.  This burst release is consistent with previous literature in 
which CS, CaP, or PMMA beads impregnated with antibiotics released 80-90% of the 
loaded drug within the first few days [11, 40].  This direct loading method, which can 
achieve very high local concentrations for very short periods of time, is not practical for a 
device intended for implantation without removal, because the biomaterial could act as a 
substrate for bacterial colonization after the majority of the drug has been released.  In 
contrast, vancomycin loaded into PLGA microspheres was released more slowly, over 
the course of 6 weeks, when the microspheres were loaded into the composite bone filler, 
achieving the target timeframe of 4-6 weeks.  The concentrations released from the bone 
filler samples remained above the MIC90 for S. aureus (approximately 1 µg/ml for 
vancomycin) for several weeks, but the duration could potentially be extended by using 
slower degrading microspheres or incorporation of antibiotic-loaded microspheres into 
the core of the samples as well as the shell [109].  
An infected wound site is an inhospitable environment for drugs to be released 
into or for bone to heal properly [19, 23, 30].  This site will have numerous types of host 
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cells, including neutrophils, monocytes, and macrophages [30].  While these cells are part 
of the body’s natural defense against bacterial infections, the resulting inflammation, 
such as would be the case with a persistent biofilm that the cells cannot remove by 
themselves, can cause more damage than good [30].  Prolonged inflammation will cause 
host response cells to be present in greater numbers and for a longer time period than 
usual and can lead to tissue death and accelerated degradation of implanted materials 
through the release of reactive oxygen species and proteolytic enzymes [30, 110-113].  
Along with the host phagocytic cells, bacterial colonies will release proinflammatory 
cytokines, such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and IL-6 [20, 30].  
These inflammatory cytokines activate osteoclasts to resorb bone and/or inhibit 
osteoblastic activity to disrupt the balance of bone removal/formation [30].   
To avoid the destruction of drug or the inefficiency of healing bone in a hostile 
environment, release of the osteogenic molecule simvastatin was delayed from the 
present bone filler material.  This delay gives the antimicrobial drugs time to act on the 
infection before bone healing would be stimulated, potentially increasing the 
effectiveness of the drug and quality of bone healing [114, 115].  Previous studies by 
Chen et al. investigated the use of BMP-2 and BMP-7 in infected femoral defects with 
and without systemic antibiotic treatment [114].  The results showed that, while high 
doses of the osteoinductive proteins were able to stimulate some bone formation without 
antibiotics, there was a significant increase in bridging of the defects when the treatment 
was combined with antibiotics, which led the authors to conclude that the timing for 
administering each drug should be investigated [114].  Thus, in a similar manner to 
current clinical practice, the two required treatments for treating IBDs could be released 
at different times from the same device.  
In research conducted by Guelcher et al., a polyurethane scaffold was loaded with 
BMP-2 and vancomycin for the treatment of infected, critically-sized femoral defects in 
rats [63].  These injectable scaffolds showed an initial burst release of BMP-2 followed 
by sustained release over the course of 3 weeks; vancomycin had a much smaller burst 
release with sustained release over the course of the 3 weeks evaluated.  The 
simultaneous release of an osteogenic molecule and antimicrobial stimulated significantly 
more bone formation than did release of BMP-2 alone.   This positive result was 
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attributed to the dual release of drugs, which allowed the infection to be controlled while 
bone healing was taking place, a critical step in achieving bone healing in an infected site 
[1, 63].  Pauly et al. compared two different doses of simvastatin and one dose of BMP-2 
in a rat tibial fracture model [116].  The different treatments were released locally from a 
polymer-coated implant and the bones evaluated mechanically [116].  The low and high 
doses of locally released simvastatin resulted in comparable maximum loads and 
torsional stiffness of the evaluated tibias [116].  The time course for testing the healing 
bones in the study was 28 and 42 days but would need to be longer if there was a critical-
sized bone defect.  To be most effective in a large defect, simvastatin would need to be 
delivered for several weeks over the course of bone healing [54, 117].  The ideal time 
delay before the stimulation of bone healing is unknown and would likely depend on the 
type and severity of the infection as well as the antimicrobial treatment.  A main 
consideration would be to allow enough time for the wound site to return to baseline 
physiological levels, e.g., pH, cell populations, and vascularity, so the drug is not wasted 
and bone healing can occur effectively.  
In work by Strobel et al., a polymeric coating was developed to release 
gentamicin, BMP-2, and insulin-like growth factor I (IGF-I) in a time-dependent manner 
[2].  Gentamicin and IGF-I were released quickly at first and followed by slow release of 
BMP-2 over several weeks [2].  An additive effect was seen on the metabolic activity of 
primary osteoblasts from the multi-drug releasing implant compared to single drug 
releasing implants [2].  Both the antimicrobial and growth factors were released 
simultaneously in vitro, although at different rates.  If these drugs were to be released into 
a contaminated bone defect, as is often the case in large bony defects, it is likely that the 
same effects on local cells would not occur due to the physiologically altered 
environment [20, 30]. 
In the present study, the delayed release of simvastatin was achieved in two 
distinct ways:  1) the physical barrier of the outer shell around the simvastatin-loaded 
core and 2) the delayed physiological effect on bone from simvastatin.   The shell and 
core design of the bone filler utilized a physical barrier to diffusion of simvastatin into 
solution that was capable of delaying release of the drug for around 12 days.  The other 
cause of delay is innate to the function of the simvastatin in vivo.   From the time that 
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simvastatin begins to act on cells, there is a 1-2 week delay before increased levels of 
BMPs are seen [118].  The physical shell method is necessary because simvastatin 
released into an infected site would still encounter a harsh environment, even if its effects 
would not be seen for 1-2 weeks.  Use of the shell and core method has another 
advantage in that the system can have both moldable and non-moldable components.  
This allows the outer shell to be moldable and conform to irregularly shaped defects, 
while the core can be pre-dried and remain in the defect site for a longer period of time. 
Bioactivity of vancomycin released in vitro was shown in two different types of 
Kirby-Bauer experiments, confirming that the ability to kill bacteria was retained when 
released for several weeks in vitro.  The traditional KB assay showed inhibition of S. 
aureus for almost a week, while the modified version in which entire bone filler samples 
were used showed inhibition for around two weeks and at significantly larger areas of 
inhibition.  The increased area of inhibition seen in the modified KB, as high as six times 
that of the traditional KB, can be attributed to several factors.  The first is that there was a 
significantly larger loading of antimicrobial drug in the entire sample than in the filter 
paper discs used in the traditional KB study.  The traditional KB study involved loading 
filter paper discs with 5 µl of release supernatant, which at its highest concentration 
would result in less than 1 µg of vancomycin being in the disc.  Even at high 
concentrations, the actual amount of antimicrobial drug being loaded into each disc and 
diffused through the relatively large agar plate will be small.  The full samples, however, 
were initially loaded with 3.75 mg of vancomycin that could diffuse into the blood agar 
plates.  It is unlikely that all of the drug would diffuse out of the sample into the agar 
because a new agar plate was used for each time point and significant inhibition was seen 
for two weeks.  The modified KB study was conducted in order to compare the release 
profiles and effectiveness of vancomycin release in different environmental conditions.  
When placed in sink conditions, vancomycin, being a hydrophilic drug, will diffuse out 
of the CS matrix quickly.  While this is a commonly used in vitro test condition, it does 
not capture the conditions of an in vivo environment.  Because it would be extremely 
difficult to replicate all of the in vivo conditions, an alternate test was used, in which the 
samples, as could be implanted into wound sites, would be releasing into a agar matrix 
under warm and humidified conditions. 
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4.5 Conclusions 
A moldable composite bone filler material was shown to release a bioactive 
antimicrobial agent in a controllable manner for six weeks while postponing the release 
of an osteogenic drug for 12 days.  A delay was intentionally designed into the system to 
avoid drug loss and inefficient healing associated with attempting to repair a bone defect 
in the presence of an infection. The temporal separation in the release of simvastatin was 
achieved by using a two part system comprising a moldable outer shell that also acted as 
a barrier and a pre-formed core.  The promising results seen from this material warrant 
further investigation of the bone filler in a rigorous infected segmental defect model to 
verify the effectiveness of the treatment in vivo. 
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Chapter 5 Testing of a Bioactive, Moldable Bone Graft Substitute in an Infected, 
Critically-Sized Defect Model 
 
5.1 Introduction 
Large infected bone defects (IBDs) are complicated to treat and require multiple 
procedures for a successful outcome [1, 2, 112, 113].  These wounds are typically caused 
by high energy trauma, which can damage the surrounding soft tissue, underlying hard 
tissue, and often lead to infection [1, 2, 112, 113].  IBDs thus have a high military 
significance, with approximately 80% of injuries sustained during Operations Enduring 
Freedom and Iraqi Freedom being the result of explosions and 50-85% of these becoming 
infected [14-16].  Although not as common, infections occur in approximately 13-18% of 
open fractures in civilians [9].  
Current treatment methods begin with extensive surgical debridement and 
irrigation combined with systemic antibiotic delivery [2, 10, 11, 105].  Once the infection 
has been eliminated, the process of healing the tissue can begin, typically with bone 
grafting [2, 10, 11, 105].  The most common and successful bone graft is the autograft, 
which has been the gold standard for over 100 years [6, 24].  The success of autografts is 
due largely to the inclusion of living osteogenic cells that have no risk of rejection 
because they come from the patient’s own body [3].  Even with the success of autografts, 
however, there are still several drawbacks, such as the need for a secondary surgical site 
to obtain the donor bone, limited grafting material, and donor site morbidity [35].   
To improve upon current treatment methods, materials that can replace bone 
autografts are being developed [3, 6, 40].  The most common materials for these bone 
graft substitutes are calcium sulfate (CS), calcium phosphate cements (CPC), 
hydroxyapatite (HA), polyurethane (PUR), and poly(lactic-co-glycolic acid) (PLGA) [41, 
42, 119, 120].  These materials are often loaded with antimicrobial or osteogenic drugs to 
increase their effectiveness at treating large IBDs [41, 121].  Newer treatments have 
focused on delivering the antibiotics locally at the site of infection to decrease the amount 
of drug needed and more effectively combat the infection [116, 122].  One common 
method of local delivery involves loading antimicrobial drugs into pellets or soaking 
pellets in drug solutions that can then be packed into the wound site for local delivery 
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[55, 123, 124].  The problem with this method is that there is little control over drug 
release, and there is often a large burst of drug within the first day or two followed by an 
extended release of sub-therapeutic concentrations [23, 40, 55, 102].  Nondegradable 
pellets and those degrading too slowly must eventually be removed so they do not create 
drug-resistant bacteria or act at niduses for further infection [23, 40, 55, 102]. 
The current work focused on the in vivo testing of a drug-releasing, CS-based, moldable 
composite bone graft substitute that was previously developed.  This composite material 
was designed to release antimicrobial and osteogenic drugs in a temporally separated 
manner to allow time for the infection to be treated prior to stimulating bone healing. 
 The effectiveness of the composite material was evaluated in an infected, critically sized 
rat femoral defect model by analyzing the survival of animals, radiography, 
microcomputed tomography, and histology.   
 
5.2 Materials & Methods 
 
5.2.1 Moldable Bone Filler 
The moldable bone filler was previously developed as a two part system 
consisting of a pre-formed core surrounded by a moldable shell [105].  The filler 
consisted of calcium sulfate (CS) (98% hemihydrate; Sigma), hyaluronan (HY) (MW 
1.323 x 105 Da; LifeCore Biomedical), simvastatin (Harorui), and PLGA microspheres 
containing vancomycin (Sigma).  Vancomycin was encapsulated into PLGA (50:50 L:G, 
acid-terminated, 0.55-0.75 dl/g I.V.; Durect Corp.) using a double emulsion method as 
previously published.  Blank (drug-free) microspheres were prepared the same way 
except for the omission of antibiotic from the first water phase.  The different core and 
shell compositions used can be seen in Table 5.1. 
Core pieces were prepared in batches by mixing 3 g dry materials with 1.4 ml 
deionized (DI) water and placing the putty into cylindrical Delrin molds (6.5 mm deep x 
3.2 mm diameter) where they were allowed to dry overnight at 40 °C overnight.  The 
shells were composed of 200 mg total material (CS, HY, and PLGA).  The dry materials 
were mixed thoroughly before the addition of 100-125 µl DI water, depending on the 
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composition.  The now moldable shell material was wrapped around the pre-dried core 
immediately prior to implantation. 
Table 5.1: Composition of bone filler composites evaluated. 
  
weight % component 
  
CS HY 
Blank-
PLGAms 
Vanc-PLGAms Simvastatin 
Blank 
Shell 75 10 15 0 0 
Core 100 0 0 0 0 
Antimicrobial 
Shell 75 10 0 15 0 
Core 100 0 0 0 0 
Osteogenic 
Shell 75 10 15 0 0 
Core 94 0 0 0 6 
Antimicrobial 
+ Osteogenic 
Shell 75 10 0 15 0 
Core 94 0 0 0 6 
 
5.2.2 Infected Femoral Defect Model 
All animal studies were conducted at the University of Kentucky in accordance 
with a protocol approved by the Institutional Animal Care and Use Committee (IACUC).  
Effectiveness of the composite bone filler in vivo was investigated using an established 
model of critically sized infected femoral defects in adult male Sprague-Dawley rats 
(375-400 g) [114, 125].  The diaphysis of one femur was exposed using a lateral 
approach and fixed using a polyacetyl plate (25 x 5 x 2.5 mm) and 6 Kirschner wires (K-
wires; 1.6 mm, threaded; Synthes).  Using guide marks on the fixation plate, a 6 mm 
defect was then made using a surgical bur as seen in Figure 5.1A.  A bovine type I 
collagen sponge (Stryker Biotech) containing 104 CFU of S. aureus (ATCC 25923) was 
placed into the defect and the wound closed in layers.  After either 6 hours (acute 
infection) or 2 weeks (chronic infection), the wounds were surgically debrided and the 
respective treatment applied, meaning that either a moldable bone filler was implanted or 
left empty as a control (Figure 5.1B).  Animals were censored from the study before the 
clinical endpoint if loss of fixation, dehiscence, or tissue necrosis around wound site was 
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observed.  The test groups evaluated can be seen in Table 5.2.  Systemic administration 
of antibiotics involved daily subcutaneous injections of ceftriaxone (50 mg/kg) for 1 
month. 
 
Figure 5.1: Segmental femoral model used.  A) Critical-sized defect with fixation plate 
and K-wires. B) Plated rat femur showing moldable bone filler implant after debridement. 
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Table 5.2: Study design for the chronic and acute infection models. Key codes: NI - non-
infected, CI - chronically infected, AI - acutely infected. 
 
Endpoint 
Group Description 4 wk 12 wk 
Empty NI, CI, AI NI, CI, AI 
Blank NI, CI, AI NI, CI, AI 
Osteogenic NI, CI, AI NI, CI, AI 
Antimicrobial CI, AI CI, AI 
Antimicrobial + Osteogenic CI, AI CI, AI 
Osteogenic + Systemic 
Antibiotics 
CI, AI CI, AI 
 
5.2.3 Analysis 
Animals were observed daily for the first 7 days post-operatively and weekly until 
the primary endpoint at either 4 or 12 weeks post-debridement.  Femurs were then 
removed by disarticulation, leaving the muscle in place to minimize disruption of the 
defect site, radiographed, and fixed in 10% buffered formalin for 2 weeks.  The femora 
were scanned by microcomputed tomography (microCT; Scanco µCT40) using a voxel 
size of 30 μm and X-ray settings of 70 kVp and 114 μA.  ImageJ was used to evaluate 
bone area within the defect site from radiographs using the K-wires as guides and tracing 
radiopaque material within the region of interest. 
Wax-it Histological Services embedded the samples from all the groups in 
poly(methyl methacrylate) (PMMA) and sectioned along the longitudinal axis of the  
femur to allow visualization of the bone defect.  Sections were cut at 10 μm, 
deplastinated, and stained using hematoxylin and eosin (H&E) or Goldner’s trichrome.   
Undecalcified specimens were fixed in 10% neutral buffered formalin, dehydrated in 
graded alcohols, and embedded in methyl methacrylate.  Sections were obtained with a 
band saw and ground to approximately 60-80 µm in thickness using an Exakt cutting-
grinding system (Exact 310 CP, Exact Technologies, Oklahoma City, OK). Stained 
sections were imaged using a Nikon Eclipse E600 microscope (Nikon) with an attached 
Olympus DP71 camera (Olympus). 
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5.2.4 Statistics 
One-way analysis of variance (ANOVA) was performed using Prism software 
(GraphPad) for analysis of bone area within the defect sites. Statistical analysis was 
determined at p values less than 0.05 and Bonferroni’s post-hoc test was performed when 
needed.   Survival was assessed using Kaplan-Meier curves and compared using log-rank 
(Mantel-Cox) test.  Survival in this case refers to the rate of censoring animals from the 
study using criteria defined in 5.2.2.   
 
5.3 Results 
 
5.3.1 Survival 
The effect of local antibiotic treatment on survival of the animals compared to 
those without any antibiotics can be seen in Figure 5.2A.  Note that while survival curves 
are shown, no animals actually died from the procedures or infection, but the figures 
show the percentage of animals that were euthanized for humane reasons or at the request 
of the attending veterinarian.  Locally released vancomycin increased survivorship by 
58% over the course of 12 weeks compared to the control groups (p=0.001).  A 
comparison of survival between chronically infected animals treated with the locally 
released antibiotics and those treated with one month of systemic antibiotics showed that 
there was no statistical difference between the rates of survival, although the local 
antibiotic groups had a final survival percentage approximately 24% higher than those 
treated with systemic antibiotics (Figure 5.2B).  Animals treated with systemic antibiotics 
did have a slightly higher survival rate than those not receiving any type of antimicrobial 
(p < 0.05, data not shown).  For the acute (6 hr) infection model, no significant difference 
was seen between animals that received no antibiotics and those treated with locally 
delivered antibiotics, although animals that received local antibiotics had a final survival 
percentage approximately 22% higher (Figure 5.2C).    Through the course of 12 weeks, 
chronically infected animals receiving no antibiotics fared worse than did those in the 
acute infection groups (Figure 5.2D).  Survivorship among acutely infected animals was 
approximately 40% higher compared to chronically infected animals (p < 0.05). 
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Figure 5.2: Survival curves over 12 wk.  A) Effect of locally released antibiotics (Abx) in 
chronically infected animals. B) Effect of local vs. systemic administration of antibiotics 
in chronically infected animals. C) Effect of locally released antibiotics in acutely 
infected animals. D) Comparison of acutely (6 hr) and chronically (2 wk) infected 
animals with no antibiotic treatment. 
 
5.3.2 MicroCT and Histology 
Representative microCT images for empty, blank, osteogenic, antimicrobial, and 
osteogenic + antimicrobial treatment groups for the acute and chronic infection models 
can be seen in Figures 5.3 and 5.4, respectively.  Acutely infected animals that received 
only antimicrobial treatment had little bone formation but did show signs of maintaining 
the cortical bone adjacent to the defect in the presence of the infection.  Animals treated 
with antimicrobial and osteogenic drugs showed the most bone formation, but it was still 
unable to bridge the defect in the presence of the infection.  
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Figure 5.3: MicroCT images of defect sites evaluated for acute infection model. 
For chronically infected animals, the most bone formation within the defect was 
seen in animals that were not infected or were treated with antimicrobials, either locally 
delivered vancomycin or systemically delivered ceftriaxone.  Animals that received no 
antimicrobial treatment did not survive to be evaluated at 12 wk. 
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Figure 5.4: MicroCT images of defect sites evaluated for chronic infection model. 
Bone growth into the defect site after 12 weeks was analyzed for chronically 
infected and non-infected animals and can be seen in Figure 5.5.  Non-infected animals 
treated with an osteogenic drug showed significantly larger bone areas within the defect 
site than infected animals receiving no antimicrobial treatment of any kind (p < 0.05).  
Infected groups receiving antimicrobials were insignificantly different from all non-
infected groups.   
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Figure 5.5: Bone areas for treatment groups at 12 weeks.  Osteo = osteogenic, Anti. = 
antimicrobial, Sys. Abx. = systemic antibiotics (Data are mean ±SD, n=4-6). 
Figure 5.6 shows sections of entire femurs from non-infected and chronically 
infected animals at 12 weeks.  Bone healing can be seen in the non-infected groups, 
particularly in the osteogenic group, but little to no bone healing was present in the 
infected groups.  These findings were supported by the bone area within the defect results 
from Figure 5.5. 
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Figure 5.6: Whole femur sections stained with Goldner’s trichrome for non-infected and 
chronically infected animals at 12 weeks. 
Representative histological thin sections stained with H&E from acutely and 
chronically infected defect sites can be seen in the Supplementary 2 and 3.  For acutely 
infected animals, empty defects showed some signs of bone healing at 4 wk, although it 
was disorganized, and a greater amount of bone healing at 12 wk.  Blank implants 
resulted in defect maintenance at 4 wk and signs of bone formation at 12 wk.  
Antimicrobials alone resulted in minor bone formation at 12 weeks, but not as much as 
the non-infected controls.  Animals receiving osteogenic and antimicrobial drugs showed 
what looks like a shell of bone formation around the site of infection. 
 
5.4 Discussion 
IBDs are difficult to treat clinically because they present two distinct challenges 
within the same wound site, an aggressive infection and a large bone defect.  The 
treatment of IBDs is often separated into two phases, the first treating the infection and 
the second repairing the bone [6, 22].  By controlling the release of antimicrobial and 
osteogenic agents in a temporal manner, the two phases of treatment can be combined 
into one device.  This is accomplished by first releasing vancomycin from the outer 
portion of the moldable bone filler followed by a delayed release of simvastatin from the 
inner core portion.  This separation is necessary due to the difficulty of eliminating 
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bacteria, which attach to damaged and necrotic tissue and even invade living bone cells, 
making removal difficult [30, 126][25, 126].  Furthermore, the bacteria can colonize and 
form a biofilm on implanted fixation hardware required to treat large bone defects [25, 
26][25, 26, 31].  Antibiotic concentrations up to 1,000X higher can be needed to treat 
biofilms compared to planktonic bacteria [25, 29, 31]. 
  The incomplete bridging within the non-infected simvastatin treated groups 
could be due to the delayed action of simvastatin.  The release of simvastatin was 
intentionally delayed by almost 2 weeks to allow time for the infection to be treated first.  
Once released from the bone filler material, it can take 3-7 days for simvastatin to 
upregulate bone morphogenetic protein 2 (BMP-2) and bone sialoprotein [118].  The total 
time from filler implantation to simvastatin having significant effects on osteoblasts is as 
much as 3 weeks, meaning the 4 week time point analyzed was insufficient for bone 
formation.  The 12 week time point then was effectively only 9 or 10 weeks from the start 
of simvastatin activity, which may be insufficient for a bone defect this large to 
significantly heal [41, 125].  Since little bone formation was seen in the non-infected 
groups, it was not surprising that there was not much bone within the defects of infected 
animals.  In addition to the delayed action of simvastatin, the negative effects of a 
persistent infection would hinder bone healing and can even cause bone loss [30, 31].    
The negative effects of the infection that was never eliminated made bone healing 
within the defect difficult, but it appears that the most bone formation was seen in 
infected animals receiving antimicrobials and osteogenic drugs.  These animals showed 
what appears to be a shell of bone formation around the site of infection, indicating that 
healing was occurring but was unable to proceed properly due to the uncontrolled 
infection.  This observation was confirmed through histological analysis of the defect 
sites in which the most bone formation was seen in the defects of animals treated with 
simvastatin.  A small amount of bone healing without the effects of infection was seen in 
the non-infected blank and osteogenic controls, likely due to the osteoconductive nature 
of the CS based material and the osteogenic effects of simvastatin.  Chronically infected 
animals that did not receive any antimicrobial treatment did not survive to be evaluated at 
the 12 week time point where the most bone formation would have been expected. 
57 
 
In the present studies, the fixation hardware used to stabilize the femur was not 
removed during the irrigation and debridement procedures but instead left in place [114, 
125].  This created a biofilm infection on the plate and wires that was difficult to treat.  
None of the infections were truly eliminated, although animals treated with locally 
released antibiotics had a significantly higher survival rate compared to the control 
groups.  This finding was likely due to the released antibiotics having high enough 
concentrations to inhibit planktonic S. aureus bacteria, but never reaching concentrations 
high enough to fully disrupt and kill the biofilm.  The higher survival rates among 
animals treated with antibiotics indicates that the systemic antibiotics had a similar 
positive effect on the infected tissue as did the locally released antibiotics but were 
unable to completely eliminate the biofilm before the course of treatment was concluded.  
Survival rates among locally released antibiotic groups were statistically the same as 
those receiving systemic antibiotics, indicating that the use of local antibiotics was 
comparable to the more commonly prescribed systemic antibiotics.  A comparison 
between the acutely and chronically infected animals at 12 weeks showed that the acute 
infection was less severe in the long term, which was likely due to the chronic infection 
having two additional weeks of unhindered growth in the defect site.  The lack of 
difference at 12 weeks between animals receiving no antibiotics and those receiving local 
antibiotics in the acutely infection model can likely be attributed to the less severe nature 
of the infection.  Even though the infection was considered less severe in terms of 
survival and initial bacterial incubation time, however, the infection still presented a 
difficult challenge to address without removal of contaminated hardware. 
 Kazemzadeh-Narbat et al. coated titanium with a multilayered coating that 
provided sustained release of a broad spectrum antimicrobial peptide (HHC-36) that was 
active against both Gram-positive and Gram-negative bacteria [127].  Antoci et al. 
covalently attached vancomycin to titanium intramedullary implants and demonstrated 
that the modified implants were able to significantly inhibit bacterial adhesion for several 
weeks in a periprosthetic infection model in rat femurs [128].  Rodríguez-Évora et al. 
delivered two different doses of BMP-2 from a segmented polyurethane/PLGA/β-
tricalcium phosphate composite into a critically sized rat calvarial defect [129].  
Histomorphometry showed that after 8 weeks the low and high dose groups had repaired 
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approximately 10 and 30% of the defects, respectively [129].  In comparison, after 12 
weeks the amount of defect repair was approximately 20% for the low dose and 60% for 
the high dose of BMP-2 [129].  In a study by Beardmore et al., the effectiveness of local 
release of tobramycin from CS pellets mixed with demineralized bone matrix was 
evaluated in an infected tibial model in sheep [46].  After three weeks, all of the control 
groups remained infected, while the locally released antibiotics were able to eliminate the 
S. aureus bacteria within the wound site [46].  Chen et al. investigated the use of BMP-2 
with and without systemic antibiotics in an infected rat femoral defect model and found 
that, while bone formation occurred in animals that received no antibiotics, there was 
significantly more bone healing in groups including antibiotics [130].  Guelcher et al. 
saw similar results using BMP-2 loaded polyurethane scaffolds [63].   Both groups 
showed that bacteria were still present in the defect site at the end of the study period, 
even in animals that received systemic or locally released antibiotics [63, 114, 130].  The 
present findings are in agreement with the previous reports that even locally released 
antibiotics well above the MIC were not enough to eliminate all the bacteria when the 
contaminated hardware was left in place.  Both of these studies showed that partial bone 
healing was possible within an infected defect site without fully eliminating the present 
bacteria [63, 130].  To better address the full extent of the problem, methods for treating 
contaminated hardware that do not rely on removal should be explored.  One such 
method is a new class of drugs that can specifically target biofilms [28, 31].  These drugs 
could be used alone or in conjunction with antibiotics in order to disrupt the biofilm 
present on the contaminated hardware and prevent new bacteria from colonizing while 
bone healing takes place [131]. 
 
5.4 Conclusions 
A composite bone graft substitute that is capable of sequentially releasing 
antimicrobial and osteogenic drugs was evaluated in a critically sized infected femoral 
defect model.  Releasing antibiotics locally at the site of infection increased survivorship 
by 58% compared to control animals and by 24% when compared to animals receiving 
systemic antibiotics.  Incomplete bone bridging was seen in treatment groups and was 
attributed to not fully eliminating the bacterial biofilm present in the bone defect.  In 
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order to fully treat both the bone defect and infection, new treatments capable of treating 
established biofilms should be investigated. 
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Chapter 6 Effectiveness of Anti-Biofilm Agents against Staphylococcus Aureus 
Biofilms and In Vitro Release from Polymeric Microspheres 
 
6.1 Introduction 
Biofilms are sessile communities of bacterial cells that differ from their 
planktonic form in a number of ways, including secreting protective extracellular 
polymeric substances (EPS) and altering their normal gene expression [27-29].  These 
infections are difficult to treat clinically and can cause increased hospital stays, costs, or 
failure of implanted devices [19, 25, 132].  The EPS makes many traditional 
antimicrobials, such as antibiotics, ineffective and prevents host defenses from reaching 
the bacterial cells [19, 25, 27, 132].  It can take 1,000X the minimum inhibitory 
concentration (MIC) of traditional antibiotics to eradicate established biofilms, amounts 
that may be unachievable via systemic delivery or potentially toxic [25, 29, 31]. 
 Current clinical practice for the treatment of a biofilm is to physically remove the 
source of the infection by removing any infected hardware, extensive debridement of 
infected tissue, and a lengthy regime of systemic antibiotics [6, 22, 25].  This process is 
both painful and costly for the patients, and success is dependent on elimination of all 
bacterial cells to prevent resurgence of the biofilm [25].  New methods of combating 
biofilms have focused largely on releasing traditional antibiotics locally at the source of 
the infection, achieving much higher concentrations than would be possible otherwise 
[122, 133].  These methods work fairly well at inhibiting the growth of biofilms but 
require large amounts of drugs to treat established biofilms and thus are not efficient 
[122, 133].   
Recently, interest has been growing in identifying drugs that specifically target 
biofilms, either inhibiting them from attaching or growing, or by disrupting existing 
biofilms [19, 27, 28].  A commonly used antibiotic for treating Staphylococcus aureus 
infections is the glycopeptide vancomycin [19, 27].  New methods of using vancomycin 
and other powerful antibiotics have focused on releasing them locally at the source of the 
infection [27, 41, 134, 135].  The MIC for MRSA when using vancomycin has been 
increasing over the years, indicating that some strains may be developing resistance [27, 
136].  The D-amino acids are a new class of anti-biofilm (ABF) agent being investigated 
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for their ability to inhibit the growth and trigger the disassembly of bacterial biofilms 
[137-139].  Certain D-amino acids are thought to work by preventing the bacteria from 
aggregating and forming a complete biofilm, which makes them much easier to treat 
[137, 138].  Lactoferrin is a protein found in the innate immune system that can act as an 
antimicrobial by iron chelation, which destabilizes the biofilm membrane [140, 141].  It 
is often used in conjunction with the rare alcohol sugar xylitol, which is commonly used 
as an oral biofilm inhibitor [140-142].  Fatty acids have also been shown to work 
synergistically with common antibiotics, such as daptomycin or vancomycin, to inhibit 
the growth of methicillin-resistant S. aureus (MRSA) infections [143, 144].  Lysostaphin 
is an endopeptidase that both inhibits and disrupts bacterial biofilms by cleaving the 
crosslinks in the cell walls of Staphlococcus spp., killing bacterial cells and preventing 
biofilm formation [76, 131]. 
 The present studies focused on screening drugs shown to inhibit biofilm 
formation at low concentrations and identify one capable of disrupting an existing 
biofilm. This ability to inhibit as well as disrupt is crucial for future use in treating 
infected hardware or tissue.  Lysostaphin was identified as an ABF drug that could both 
inhibit and disrupt S. aureus biofilms and was chosen for additional studies on loading 
the protein into a drug delivery vehicle. 
 
6.2 Materials & Methods 
 The following drugs were investigated for their ability to inhibit or disrupt S. 
aureus biofilms:, lysostaphin (lyso) (AMBI Products), xylitol (ACROS Products), 
lactoferrin (Sigma), D-phenylalanine (D-Phe) (ACROS Products), D-proline (D-Pro) 
(ACROS Products), D-tyrosine (D-Tyr) (ACROS Products), L-phenylalanine (L-Phe) 
(Sigma), L-proline (L-Pro) (Sigma), L-tyrosine (L-Tyr) (Sigma), and vancomycin (vanc) 
(Sigma). 
 
6.2.1 Anti-Biofilm Assays 
 The ABF assays used to evaluate the different drugs were adapted from those 
described by Hochbaum et al. [137].  A schematic for each type of assay can be seen in 
Figure 6.1.  For inhibition studies, 215 µl brain heart infusion (BHI) supplemented with 
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1% glucose and 2% NaCl were added to 96-well plates with 25 µl of the drug of interest 
and 10 µl of a 1/100 dilution of S. aureus (ATCC 25923) from an overnight culture.  For 
disruption studies, the bacteria were added to the supplemented BHI and allowed to grow 
in 96-well plates for 24 hours prior to a refresh of the media and addition of the 
treatment.  After 24 hours of exposure, the media was carefully removed and each well 
rinsed once with phosphate-buffered saline (PBS).  Next, 250 µl of a 0.1% crystal violet 
solution was added to each well and allowed to sit for 15 minutes.  The stain was then 
removed and each well rinsed twice with deionized water.  To quantify the amount of 
stained bacteria, 250 µl of ethanol was added to each well and allowed to shake for 2 
hours.  Absorbances were measured at 595 nm after diluting the eluted stain.  Data are 
reported as optical density (OD).  For dual treatment studies, after the first 24 hours of 
exposure to the drug, the media was refreshed and another treatment (or none) added. 
 
Figure 6.1: Schematic of ABF assays.  A: Yellow indicates BHI media, and red dots are 
S. aureus cells, while red line patterns are S. aureus biofilms; blue indicates added 
treatments; purple indicates cells stained with crystal violet. B: Picture of stained plate; 
left column was not inoculated with bacteria. 
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6.2.2 Radio-labeling 
Lysostaphin was labeled with 125I using the IODO-GEN Iodination Reagent 
(Pierce).  First, a 1 mg/ml stock solution of IODO-GEN was made by dissolving in 
chloroform, and then 250 µl of this solution was transferred to another tube and 
evaporated with nitrogen.  Next, 100 µl of a 1 mg/ml stock solution of lysostaphin was 
added along with 16 µl of 125I and allowed to react at room temperature for 10 minutes.   
A protein desalting spin column (Pierce) was used to separate free 125I from the labeled 
protein by spinning at 1500g for 2 minutes and precipitating the protein into a solution of 
20 wt% trichloroacetic acid (TCA) and PBS with 10% bovine serum albumin (BSA).  
The radioactivity of the labeled protein, labeled drug-loaded microspheres (see next 
section), and labeled release supernatants was measured using a WIZARD2 Automatic 
Gamma Counter (Perkin Elmer 2470). 
 
6.2.3 PLGA Microsphere Fabrication 
 PLGA microspheres (PLGAms) were fabricated using a double emulsion 
technique (W1/O/W2).  The oil phase consisted of 13% w/v PLGA (75:25 L:G, acid-
terminated, I.V. 0.55-0.75 dl/g; Durect Corp.) dissolved in dichloromethane (DCM).  The 
first emulsion was created by adding 0.11% v/v of PBS, either blank or drug-loaded (65 
mg/ml lysostaphin), to the PLGA-DCM solution and sonicating for 10 seconds at 25 W.  
For the radiolabeled lysostaphin microspheres, labeled protein was added to the stock 
protein immediately before creating the first emulsion.  This  W1/O emulsion was then 
added to 300 ml of deionized water (containing 1% methylcellulose and 4% NaCl) in a 
dropwise manner and homogenized (2000 rpm) for 3 minutes to create the second 
emulsion.  The resulting suspension of microspheres was stirred overnight at 600 rpm to 
evaporate the solvent.  The microspheres were then collected by centrifugation, washed 
using deionized water, and lyophilized. 
 
6.2.4 Release Profiles and Bioactivity 
 For release profile studies, 30 mg of PLGA microspheres loaded lysostaphin 
(labeled or non-labeled) were placed in 2 ml of PBS and shaken at 37°C in a water bath.  
At predetermined time points, the samples were centrifuged at 327g force for 3 minutes 
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and the supernatant completely changed.  The collected supernatants were frozen until 
analysis.  Labeled lysostaphin microspheres were used made to analyze the loading and 
release characteristics of lysostaphin while the non-labeled microspheres were used in the 
bioactivity studies.  The release profiles for the microspheres were analyzed by 
measuring 1 ml of release supernatant using the WIZARD2 Automatic Gamma Counter 
(Perkin Elmer 2470).  Bioactivity was determined by comparing the effectiveness of 
release supernatants at inhibiting or disrupting biofilm formation compared to known 
lysostaphin concentrations. 
 
6.2.5 Statistical Analysis 
 One-way analysis of variance (ANOVA) was performed using Prism software 
(GraphPad). Statistical analysis was determined at p values less than 0.05.  Tukey’s post-
hoc test was performed as needed. 
 
6.3 Results 
 
6.3.1 ABF Drug Screening 
 Results from the biofilm inhibition study can be seen in Figure 6.2.  All of the 
lysostaphin and vancomycin concentrations, down to 0.5 and 5 µg/ml, respectively, were 
able to inhibit biofilm formation comparable to the negative control (p < 0.0001 
compared to negative control).  None of the other treatments, i.e., xylitol, lactoferrin, 
xylitol+lactoferrin, or D-amino acids, inhibited the biofilm from growing. 
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Figure 6.2: Biofilm inhibition results for the drugs investigated.  Data are mean ± SD, 
n=8. 
 Results from the biofilm disruption studies can be seen in Figure 6.3.  
Lysostaphin was able to disrupt the existing biofilm at concentrations as low as 5 µg/ml 
(p < 0.0001), but the xylitol, lactoferrin, or amino acids did not have any measureable 
effect. None of the vancomycin concentrations investigated showed any significant 
difference from the negative control.  
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Figure 6.3: Biofilm disruption results for the drugs investigated.  Data are mean ± SD, 
n=8. 
 Based on the previous inhibition and disruption results, additional studies on 
lysostaphin were performed to determine at what lower concentrations it was effective 
(Figure 6.4).  Lysostaphin was able to inhibit biofilm formation at concentrations as low 
as 0.1 µg/ml (p < 0.05) and disrupt existing biofilms starting at 1 µg/ml (p < 0.001) and 
up. 
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Figure 6.4: Biofilm inhibition and disruption results for lysostaphin at decreasing 
concentrations. Data are mean ± SD, n=8. 
 Dual treatment results can be seen in Figure 6.5.  Treatment once with lysostaphin 
at concentrations as low as 10 µg/ml resulted in dispersion of biofilm that was not able to 
re-grow after 24 hours with new BHI media (p < 0.0001).  All dual treatments with 
lysostaphin resulted in biofilm disruption, but vancomycin alone had little effect.    
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Figure 6.5: Biofilm disruption with lysostaphin dual treatment. Data are mean ±SD, n=8. 
 
6.3.2 In vitro release and activity of lysostaphin 
Encapsulation of lysostaphin into PLGAms resulted in a final loading of 8.5wt%, 
encapsulation efficiency (EE) of 65%, and average size of 40±15 µm.  Profiles for release 
of lysostaphin encapsulated in PLGAms can be seen in Figure 6.6.  When released from 
PLGA microspheres, lysostaphin reached a maximum instantaneous concentration of 57 
µg/ml at day one and remained above 5 µg/ml for 19 days. 
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Figure 6.6: Release profile for lysostaphin-loaded PLGAms.  Data are mean ±SD, n=5. 
The bioactivity of lysostaphin in release supernatants can be seen in Figures 6.7 and 
6.8.  Release supernatants were able to inhibit biofilm formation and disrupt existing 
biofilms for 4 days when compared to the negative control and their corresponding 
blanks (bPLGAms) (p < 0.05).  Compared to the negative control, release supernatants 
inhibited biofilm formation by 43% on day 1 and 81, 86, 86, 41, and 22% for days 2, 3, 4, 
5, and 6, respectively (Figure 6.7).  When evaluated in the disruption study, release 
supernatants decreased the amount of biofilm by 33% on day 1 and 52, 52, 61, 16, and 0 
% for days 2, 3, 4, 5, and 6, respectively (Figure 6.8). After day 4 of release, there were 
no statistically significant differences between the drug-loaded PLGAms release 
supernatants, blank PLGAms release supernatants, and negative control.   
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Figure 6.7: Ability of lysostaphin released from PLGAms to inhibit biofilms. Data are 
mean ±SD, n=3-8. 
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Figure 6.8: Ability of lysostaphin released from PLGAms to disrupt biofilms. Data are 
mean ±SD, n=3-8. 
 
6.4 Discussion 
One of the more commonly used antibiotics for S. aureus infections is 
vancomycin, which works by interfering with cell wall formation in Gram-positive 
bacteria [115, 145-147].  Vancomycin works well at inhibiting biofilm formation because 
it acts on the cell walls before the protective EPS can be formed [27, 29].  However, once 
the biofilm has formed, vancomycin is effective at only concentrations 1,000X higher 
than the MIC [25, 29, 31].  This is due to the protective nature of the EPS which acts as a 
physical barrier between antimicrobials and the bacterial cells within the biofilm [25, 28, 
29, 31].  One common method of circumventing this problem is to deliver the antibiotic 
locally at the site of infection to avoid systemic toxicity and achieve high concentrations 
with little drug waste [27, 115, 148].  Local delivery methods can often achieve high 
concentrations initially followed by low levels for days, weeks, or even months [27, 146, 
148].  Gálvez-López et al. evaluated the release kinetics of 11 different types of antibiotic 
loaded bone cements and found that while effective MIC were seen for around 30 days in 
some cases, none of the concentrations reached would be effective at disrupting a biofilm 
[149].  In clinical practice, antibiotic loaded beads are an accepted osteomyelitis 
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treatment option.  When combined with systemic antibiotics and debridements these 
antibiotic loaded beads are effective in eliminating chronic infections even when only 
releasing effective concentrations for a few days [40, 102].  Despite the promising release 
kinetics of many of these systems, there is still great difficulty in treating an established 
biofilm with local antibiotics alone due to the inability of the antibiotics to penetrate the 
EPS and act on the bacteria [25, 27].  The results from the present study show trends 
consistent with the literature [31, 150], with vancomycin inhibiting biofilm formation at 
concentrations as low as 5 µg/ml but being unable to disrupt an existing biofilm at 
concentrations as high as 2,000 µg/ml.  Consequently, although vancomycin may not be 
the best choice to treat an existing biofilm, it can act as a preventative agent to keep 
bacteria from growing initially or re-growing (persisting) after treatment.  Because of the 
difficulty of using traditional treatments, drugs that specifically target biofilms are of 
great interest [28, 31]. 
A class of agents that has shown potential for use as ABF agents are the D-amino 
acids [137-139].  Hochbaum et al. compared the effectiveness of D and L isomers of 
proline, tyrosine, phenylalanine, tryptophan (Trp), and leucine (Leu) at inhibiting S. 
aureus biofilms in vitro at concentrations ranging from 0-500 µM [137].  It was found 
that the D-Phe and D-Pro were effective at only the highest concentration of 500 µM, 
while the D-Tyr was effective at 100 and 500 µM [137].  A cocktail of all three D-amino 
acids was found to be effective at inhibiting biofilm formation at concentrations as low as 
10 µM [137].  None of the D-tryptophan, D-leucine, or L isomer treatments had any effect 
on the biofilms [137].  Kolodkin-Gal et al. reported activities for D-Tyr at 3 µM, D-
methionine (D-Met) at 2 mM, D-tryptophan at 5 mM, and D-leucine at 8.5 mM for 
Bacillus subtilis [138].  A combination of all four amino acids was found to have a MIC 
of approximately 10 nM [138].  Against S. aureus, D-Tyr was effective at inhibiting 
biofilms at 50 µM, and a mixture of D-Tyr, D-Leu, D-Met, and D-Trp was effective at 15 
nM of each amino acid.    None of the D-amino acids investigated in the present study had 
any effect on inhibiting or disrupting biofilms when compared to their inactive L-isomers.  
It may be that higher concentrations were needed to see the desired effect, but higher 
dose requirements make incorporation into a device much more challenging.  In a recent 
study by Sanchez et al., D-amino acids were evaluated in vitro for their effectiveness 
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before being delivered locally from a scaffold in an infected segmental defect model 
[151].  D-Phe, D-Met, D-Pro, and D-Trp were shown to be effective at reducing the 
biomass of S. aureus biofilms at concentrations greater than 1 mM [151].  When tested in 
vivo, a cocktail of D-Met, D-Pro, and D-Trp at concentrations of 5 and 10 mM 
significantly reduced the bacterial counts and number of infected bone samples harvested 
[151].  The D-amino acids are being investigated for use as an ABF agent due to their 
wide spectrum of use and ability to work synergistically with each other to inhibit biofilm 
formation.  However, the varied effective concentrations and high amounts usually 
needed to disrupt existing biofilms may limit their use without being combined with 
another agent to increase activity.   
 Lactoferrin and xylitol are two ABF agents that are under investigation for their 
ability to inhibit biofilm growth when used synergistically [140, 142].  Lactoferrin is an 
iron-chelating agent that is able to destabilize the bacterial membrane, and xylitol is a 
rare sugar alcohol that inhibits the ability of the bacteria to respond to the iron chelation 
caused by lactoferrin [140].  In a study by Ammon et al., lactoferrin and xylitol together 
showed a 1-2 log reduction in the bacterial load of MRSA [142].  This effect was 
increased to a 6-log reduction when combined with a silver-eluting wound dressing 
[142].  In the current study, neither lactoferrin nor xylitol by themselves or together had 
any effect at inhibiting or disrupting biofilms.  Because their effectiveness can be 
increased significantly with the addition of other antimicrobials, it may be worth 
investigating their potential use in combined ABF treatments.   
Lysostaphin is an antibacterial enzyme that acts on the pentaglycine crosslinks in 
S. aureus cell walls [76].  Wu et al. reported that lysostaphin was able to kill planktonic 
S. aureus at concentrations as low as 0.001 µg/ml (MIC90), and it disrupted existing 
biofilms at concentrations as low as 12 µg/ml even when 800 µg/ml vancomycin or 
clindamycin was not effective [76].  Lysostaphin was also shown to have synergistic 
effects with common antibiotics, such as clarithromycin and doxycycline [131].  In the 
present studies, lysostaphin was shown to disrupt biofilm formation at concentrations as 
low as 10 µg/ml and inhibit biofilm formation starting at 0.1 µg/ml.  The low dose 
requirements for lysostaphin to inhibit biofilm formation make it a good potential 
candidate for prolonged delivery from a biomaterial where a moderate burst would be 
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effective enough to disrupt the existing biofilm and the subsequent low levels of release 
concentrations would be enough to inhibit future biofilm development. 
When released from PLGA microspheres, lysostaphin reached a maximum 
concentration of 57 µg/ml at day one, and was released in a controlled manner capable of 
not only inhibiting biofilm formation but also disrupting existing S. aureus biofilms for 4 
days.  From the initial ABF assays characterizing the effectiveness of lysostaphin, it was 
expected that concentrations above 0.5 µg/ml would inhibit biofilm formation and that 10 
µg/ml would disrupt existing biofilms.  Due to the nature of the ABF assay, release 
supernatants must be diluted by 2X to be evaluated.  This means that release supernatants 
would need to have initial concentrations around 1 µg/ml or 10 µg/ml, respectively, to 
inhibit or disrupt biofilms.  Inhibition would, therefore, be expected for days 1-13 of 
release and disruption for the first 4-5 days.  It is likely that fabrication of the 
lysostaphin-loaded PLGAms resulted in some inactivation of the protein, reducing the 
effectiveness at combating biofilms [152-154].  Addition of a sugar, such as sucrose or 
trehalose, during the encapsulation process can protect the protein and increase activity 
[155, 156].   
 
6.5 Conclusions 
 Lysostaphin was confirmed as an ABF agent capable of both inhibiting biofilm 
growth and disrupting existing biofilms.  Furthermore, lysostaphin could be encapsulated 
into PLGAms and released over time in vitro, maintaining its ability to inhibit and disrupt 
biofilms for 4 days.  The observed antibiofilm activity at concentrations easily obtained 
from drug delivery vehicles or other biomaterials gives lysostaphin interesting potential 
as an antimicrobial treatment.  The promising results seen from this study warrant further 
investigation of lysostaphin and its potential to be incorporated into an ABF biomaterial.  
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Chapter 7 Conclusions 
 
A moldable, biocompatible, and biodegradable bone graft substitute has been 
developed which is capable of being loaded with therapeutic drugs for the treatment of 
infected bone defects.  Initial studies involved evaluating the mechanical and degradation 
properties of composites with different ratios of components.  The ability to interchange 
the type of plasticizer used or microspheres embedded enable the degradation time and 
drug release profiles to be tailored to specific applications.   
Typical treatment for infected bone defects involves two separate sets of 
procedures, the initial treatment for the infected tissue followed by bone grafting.  In 
order to combine these two treatment steps into one procedure, the moldable bone 
grafting material developed previously was modified to deliver drugs in a temporally 
separated manner.  This two-layered system is capable of delivering antibiotics in vitro 
for clinically relevant periods of time and delaying the release of osteogenic drugs to 
mimic a two-step procedure. 
In order to test the effectiveness of the developed bone graft substitute at treating 
an IBD, an established critically sized infected rat femoral defect model was used.  
Composites that released antibiotics locally increased survivorship of animals when 
compared to those receiving systemic antibiotics.  This indicates that the developed 
material was as effective as more commonly used clinical methods at treating biofilm 
infections.  There was no difference in the new bone formation of the treatment groups 
and non-infected control groups, indicating that the timeframe investigated was not long 
enough and that the infection, which was never fully eliminated, had a negative effect on 
the newly forming bone. 
When investigating the ability of different drugs to treat biofilms, even very high 
doses of antibiotic were unable to disrupt an existing biofilm.  Lysostaphin was identified 
as a potential anti-biofilm agent which was capable of both disrupting and inhibiting 
biofilms at low concentrations.  The loading of lysostaphin into polymeric microspheres 
was able to extend the release and increase the therapeutic potential of the drug.  
Lysostaphin shows great promise as an anti-biofilm drug capable of being incorporated 
into antimicrobial biomaterials or devices. 
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Infected bone defects as a result of high energy trauma are often contaminated 
with multiple species of bacteria and can be irregular in shape.  Since the drug-releasing 
components are swappable, without significant effect on the degradation time or strength 
of the material, it would be possible to incorporate species-specific antibiotics alone or in 
conjunction with anti-biofilm agents for treatment of challenging biofilm infections.  The 
inclusion of osteogenic or angiogenic growth factors in addition to the antimicrobials 
could further increase the therapeutic potential of the bone graft substitute to regrow bone 
in complex defects.   
This work shows that a moldable and biodegradable bone graft substitute can be 
modified to release different drugs in a controllable manner.  The composite material 
developed is capable of treating a local infection with the same efficacy as systemic 
antibiotics while providing additional therapeutic benefits, such as space maintenance 
and the delivery of an osteogenic drug and osteoconductive materials.   
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Appendix A Supplemental Figures 
 
Supplemental 1: Full results from free antibiotic release studies. Data are mean ±SD, n=5.  
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Appendix B Supplemental Figures 
 
 
Supplemental 2: Micrographs of defect sites for paired sections stained with H&E at 4 
and 12 wk for acutely infected animals. 
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Supplemental 3: Micrographs of defect sites stained with H&E (left) and Goldner’s 
trichrome (right) at 4 and 12 wk for chronically infected animals. 
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